DIAGNOSTICS AND THERAPEUTICS FOR OSTEOPOROSIS

Abstract: Diagnostics and therapeutics for osteoporosis, which are based on the identification of the subject's IL-1 haplotype pattern are described.

Description: Diagnostics and Therapeutics for Osteoporosis 1. Background of the Invention Osteoporosis In 1993, osteoporosis was identified as "one ofthe leading diseases of women" by Bernadine Healy, MD, then director ofthe National Institutes of Health. Complications following osteoporosis fractures are the fourth leading cause of death for women over the age of 65, following heart disease, cancer and stroke. It is the leading cause of disability in the United States and the most common cause of hip fracture. Twenty-five million Americans suffer from osteoporosis, of which 85% are women. Type 1 osteoporosis, which is postmenopausal osteoporosis stemming from loss of estrogen, affects more than half of all women over 65 and has been detected in as many as 90 percent of women over age 75. Type II or senile osteoporosis which is strictly age related, affects both men and women usually over the age of seventy. Type III, the newest classification affecting both sexes, is drug-induced, for example, by long-term steroid therapy, known to accelerate bone loss. Patient groups that receive long term steroid therapy include asthmatics (7 million over the age of 18 in the United States) as well a patients with rheumatoid arthritis or other autoimmune diseases. Type IV is caused by an underlying disease such as rheumatoid arthritis (prevalence of 1-2% in the population). Osteoporosis is responsible for a majority ofthe 1.5 million bone fractures each year leading to disabilities costing 10 billion dollars in medical, social and nursing- home costs. Even in the best hands, 40% of patients 65 years of age or older will not survive two years following a hip fracture. In 1991, one in three American women were 50 years or older. The baby boom generation will begin to enter this age group in 1996. Because the average woman lives some thirty years after menopause, with present trends, osteoporosis threatens to be one ofthe biggest health threats of modern times. Lifestyle can be a factor in onset of osteoporosis and in particular can be an important factor in building and maintaining healthy bone mass to prevent osteoporosis. Currently, persons under 65 are more likely than their parents to have had a sedentary lifestyle, bad eating habits, increased alcohol and caffeine intake, and a history of greater medication associated with bone loss. It is also clear that there is a genetic predisposition to the development of osteoporosis (see WO 94/03633 for a discussion of genetic factors in osteoporosis, which is herein incorporated by reference). It would therefore be useful to be able to identify early those individuals at greatest risk for developing osteoporosis so that the individual can be counseled to make appropriate life style changes or institute other therapeutic interventions. For example, calcium supplements and exercise have been shown to be valuable preventive factors if used during a critical early age window. Hormone replacement therapy (HRT) has also been used successfully to combat osteoporosis occurring after menopause. HRT may be of greatest benefit if used early in the disease process before major bone loss has occurred. Since HRT has potentially serious side-effects, it would be useful for women to known their personal risk level for osteoporosis when making decisions about the use of HRT versus other interventions aimed at reducing the risk of developing osteoporosis. The following published patent applications describe a variety of methods for diagnosing, monitoring and/or treating osteoporosis: WO 94/20615, WO 95/01995, WO 94/14844, EP93113604, WO/8809457, WO93/11149 and WO/9403633. The following references describe the association of various IL-1 gene polymorphisms in osteoporosis: U.S. Patent No. 5,698,399; Eastell, R. et al., (1998) Bone 23 (5S): S375; Eastell, R. et al. and Keen, RW et al., (1998) Bone 23: 367-371. Genetics ofthe IL-1 Gene Cluster The IL-1 gene cluster is on the long arm of chromosome 2 (2ql3) and contains at least the genes for IL-lα (IL-1 A), IL-lβ (IL-1B), and the IL-1 receptor antagonist (IL-1RN), within a region of 430 Kb (Nicklin, et al. (1994) Genomics, 19: 382- 4). The agonist molecules, IL-lα and IL-lβ, have potent pro-inflammatory activity and are at the head of many inflammatory cascades. Their actions, often via the induction of other cytokines such as IL-6 and IL-8, lead to activation and recruitment of leukocytes into damaged tissue, local production of vasoactive agents, fever response in the brain and hepatic acute phase response. All three IL-1 molecules bind to type I and to type II IL-1 receptors, but only the type I receptor transduces a signal to the interior ofthe cell. In contrast, the type II receptor is shed from the cell membrane and acts as a decoy receptor. The receptor antagonist and the type II receptor, therefore, are both anti-inflammatory in their actions. Inappropriate production of IL-1 plays a central role in the pathology of many autoimmune and inflammatory diseases, including rheumatoid arthritis, inflammatory bowel disorder, psoriasis, and the like. In addition, there are stable inter-individual differences in the rates of production of IL-1, and some of this variation may be accounted for by genetic differences at IL-1 gene loci. Thus, the IL-1 genes are reasonable candidates for determining part ofthe genetic susceptibility to inflammatory diseases, most of which have a multifactorial etiology with a polygenic component. Certain alleles from the IL-1 gene cluster are known to be associated with particular disease states. For example, IL-1RN (VNTR) allele 2 (U.S. Patent No. 5,698,399) and IL-1RN (VNTR) allele 1 (Keen RW et al., (1998) Bone 25:367-371) have been reported to be associated with osteoporosis. Further IL-1RN (VNTR) allele 2 has been reported to be associated with nephropathy in diabetes mellitus (Blakemore, et al. (1996) Hum. Genet. 97(3): 369-74), alopecia areata (Cork, et al, (1995) J. Invest. Dermatol. 104(5 Supp.): 15S-16S; Cork et al. (1996) Dermatol Clin 14: 671-8), Graves disease (Blakemore, et al. (1995) J. Clin. Endocrinol. 80(1): 111-5), systemic lupus erythematosus (Blakemore, et al. (1994) Arthritis Rheum. 37: 1380-85), lichen sclerosis (Clay, et al. (1994) Hum. Genet. 94: 407-10), and ulcerative colitis (Mansfield, et al. (1994) Gastoenterol. 106(3): 637-42)). In addition, the IL-1 A allele 2 from marker -889 and IL-IB (Taql) allele 2 from marker +3954 have been found to be associated with periodontal disease (U.S. Patent No. 5,686,246; Kornman and diGiovine (1998) Ann Periodont 3: 327-38; Hart and Kornman (1997) Periodontol 2000 14: 202-15; Newman (1997) Compend Contin Educ Dent 18: 881-4; Kornman et al. (1997) J. Clin Periodontol 24: 72-77). The IL-1A allele 2 from marker -889 has also been found to be associated with juvenile chronic arthritis, particularly chronic iridocyclitis (McDowell, et al. (1995) Arthritis Rheum. 38: 221-28 ). The IL-IB (Taql) allele 2 from marker +3954 of IL-IB has also been found to be associated with psoriasis and insulin dependent diabetes in DR3/4 patients (di Giovine, et al. (1995) Cytokine 7: 606; Pociot, et al. (1992) Eur J. Clin. Invest. 22: 396-402). Additionally, the IL-1RN (VNTR) allele 1 has been found to be associated with diabetic retinopathy (see USSN 09/037472, and PCT/GB97/02790). Furthermore allele 2 of IL-1RN (VNTR) has been found to be associated with ulcerative colitis in Caucasian populations from North America and Europe (Mansfield, J. et al., (1994) Gastroenterology 106: 637-42). Interestingly, this association is particularly strong within populations of ethnically related Ashkenazi Jews (PCT WO97/25445). Genotype Screening Traditional methods for the screening of heritable diseases have depended on either the identification of abnormal gene products (e.g., sickle cell anemia) or an abnormal phenotype (e.g., mental retardation). These methods are of limited utility for heritable diseases with late onset and no easily identifiable phenotypes such as, for example, vascular disease. With the development of simple and inexpensive genetic screening methodology, it is now possible to identify polymorphisms that indicate a propensity to develop disease, even when the disease is of polygenic origin. The number of diseases that can be screened by molecular biological methods continues to grow with increased understanding of the genetic basis of multifactorial disorders. Genetic screening (also called genotyping or molecular screening), can be broadly defined as testing to determine if a patient has mutations (alleles or polymorphisms) that either cause a disease state or are "linked" to the mutation causing a disease state. Linkage refers to the phenomenon th DNA sequences which are close together in the genome have a tendency to be inherited together. Two sequences may be linked because of some selective advantage of co-inheritance. More typically, however, two polymoφhic sequences are co-inherited because ofthe relative infrequency with which meiotic recombination events occur within the region between the two polymoφhisms. The co-inherited polymoφhic alleles are said to be in linkage disequilibrium with one another because, in a given human population, they tend to either both occur together or else not occur at all in any particular member ofthe population. Indeed, where multiple polymoφhisms in a given chromosomal region are found to be in linkage disequilibrium with one another, they define a quasi-stable genetic "haplotype." In contrast, recombination events occurring between two polymoφhic loci cause them to become separated onto distinct homologous chromosomes. If meiotic recombination between two physically linked polymoφhisms occurs frequently enough, the two polymoφhisms will appear to segregate independently and are said to be in linkage equilibrium. While the frequency of meiotic recombination between two markers is generally proportional to the physical distance between them on the chromosome, the occurrence of "hot spots" as well as regions of repressed chromosomal recombination can result in discrepancies between the physical and recombinational distance between two markers. Thus, in certain chromosomal regions, multiple polymoφhic loci spanning a broad chromosomal domain may be in linkage disequilibrium with one another, and thereby define a broad-spanning genetic haplotype. Furthermore, where a disease-causing mutation is found within or in linkage with this haplotype, one or more polymoφhic alleles ofthe haplotype can be used as a diagnostic or prognostic indicator ofthe likelihood of developing the disease. This association between otherwise benign polymoφhisms and a disease-causing polymoφhism occurs if the disease mutation arose in the recent past, so that sufficient time has not elapsed for equilibrium to be achieved through recombination events. Therefore identification of a human haplotype which spans or is linked to a disease- causing mutational change, serves as a predictive measure of an individual's likelihood of having inherited that disease-causing mutation. Importantly, such prognostic or diagnostic procedures can be utilized without necessitating the identification and isolation ofthe actual disease-causing lesion. This is significant because the precise determination ofthe molecular defect involved in a disease process can be difficult and laborious, especially in the case of multifactorial diseases such as inflammatory disorders. Indeed, the statistical correlation between an inflammatory disorder and an IL-1 polymoφhism does not necessarily indicate that the polymoφhism directly causes the disorder. Rather the correlated polymoφhism may be a benign allelic variant which is linked to (i.e. in linkage disequilibrium with) a disorder-causing mutation which has occurred in the recent human evolutionary past, so that sufficient time has not elapsed for equilibrium to be achieved through recombination events in the intervening chromosomal segment. Thus, for the puφoses of diagnostic and prognostic assays for a particular disease, detection of a polymoφhic allele associated with that disease can be utilized without consideration of whether the polymoφhism is directly involved in the etiology of the disease. Furthermore, where a given benign polymoφhic locus is in linkage disequilibrium with an apparent disease-causing polymoφhic locus, still other polymoφhic loci which are in linkage disequilibrium with the benign polymoφhic locus are also likely to be in linkage disequilibrium with the disease-causing polymoφhic locus. Thus these other polymoφhic loci will also be prognostic or diagnostic ofthe likelihood of having inherited the disease-causing polymoφhic locus. Indeed, a broad-spanning human haplotype (describing the typical pattern of co-inheritance of alleles of a set of linked polymoφhic markers) can be targeted for diagnostic puφoses once an association has been drawn between a particular disease or condition and a corresponding human haplotype. Thus, the determination of an individual's likelihood for developing a particular disease of condition can be made by characterizing one or more disease-associated polymoφhic alleles (or even one or more disease-associated haplotypes) without necessarily determining or characterizing the causative genetic variation. 2. Summary of the Invention In one aspect, the present invention provides novel methods and kits for determining whether a female subject is predisposed to developing osteoporosis, comprising identifying the IL-1 haplotype pattern ofthe female, wherein the presence of haplotype pattern 1 indicates that the female is susceptible to larger bone loss and/or increased risk of fracture during the early menopausal years and the presence of haplotype pattern 2 indicates that the female is susceptible to larger bone loss and/or increased risk of fracture during post-menopause . IL-1 haplotype patterns can be identified by detecting any ofthe component alleles using any of a variety of available techniques, including: 1) performing a hybridization reaction between a nucleic acid sample and a probe that is capable of hybridizing to the allele; 2) sequencing at least a portion ofthe allele; or 3) determining the electrophoretic mobility ofthe allele or fragments thereof (e.g., fragments generated by endonuclease digestion). The allele can optionally be subjected to an amplification step prior to performance ofthe detection step. Preferred amplification methods are selected from the group consisting of: the polymerase chain reaction (PCR), the ligase chain reaction (LCR), strand displacement amplification (SDA), cloning, and variations ofthe above (e.g. RT-PCR and allele specific amplification). Oligonucleotides necessary for amplification may be selected, for example, from within the IL-1 gene loci, either flanking the marker of interest (as required for PCR amplification) or directly overlapping the marker (as in ASO hybridization). In a particularly preferred embodiment, the sample is hybridized with a set of primers, which hybridize 5' and 3' in a sense or antisense sequence to the vascular disease associated allele, and is subjected to a PCR amplification. An allele may also be detected indirectly, e.g. by analyzing the protein product encoded by the DNA. For example, where the marker in question results in the translation of a mutant protein, the protein can be detected by any of a variety of protein detection methods. Such methods include immunodetection and biochemical tests, such as size fractionation, where the protein has a change in apparent molecular weight either through truncation, elongation, altered folding or altered post-translational modifications. In another aspect, the invention features kits for performing the above- described assays. The kit can include a nucleic acid sample collection means and a means for determining whether a subject carries at least one allele comprising an IL-1 haplotype. The kit may also contain a control sample either positive or negative or a standard and/or an algorithmic device for assessing the results and additional reagents and components including: DNA amplification reagents, DNA polymerase, nucleic acid amplification reagents, restrictive enzymes, buffers, a nucleic acid sampling device, DNA purification device, deoxynucleotides, oligonucleotides (e.g. probes and primers) etc.. As described above, the control may be a positive or negative control. Further, the control sample may contain the positive (or negative) products ofthe allele detection technique employed. For example, where the allele detection technique is PCR amplification, followed by size fractionation, the control sample may comprise DNA fragments ofthe appropriate size. Likewise, where the allele detection technique involves detection of a mutated protein, the control sample may comprise a sample of mutated protein. However, it is preferred that the control sample comprises the material to be tested. For example, the controls may be a sample of genomic DNA or a cloned portion of the IL-1 gene cluster. Preferably, however, the control sample is a highly purified sample of genomic DNA where the sample to be tested is genomic DNA. The oligonucleotides present in said kit may be used for amplification ofthe region of interest or for direct allele specific oligonucleotide (ASO) hybridization to the markers in question. Thus, the oligonucleotides may either flank the marker of interest (as required for PCR amplification) or directly overlap the marker (as in ASO hybridization). Information obtained using the assays and kits described herein (alone or in conjunction with information on another genetic defect or environmental factor, which contributes to osteoporosis) is useful for determining whether a non-symptomatic subject has or is likely to develop the particular disease or condition. In addition, the information can allow a more customized approach to preventing the onset or progression ofthe disease or condition. For example, this information can enable a clinician to more effectively prescribe a therapy that will address the molecular basis ofthe disease or condition. In yet a further aspect, the invention features methods for treating or preventing osteoporosis in a subject by administering to the subject an appropriate therapeutic ofthe invention. In still another aspect, the invention provides in vitro or in vivo assays for screening test compounds to identify therapeutics for treating or preventing the development of osteoporosis. In one embodiment, the assay comprises contacting a cell transfected with a causative mutation that is operably linked to an appropriate promoter with a test compound and determining the level of expression of a protein in the cell in the presence and in the absence ofthe test compound. In a preferred embodiment, the causative mutation results in decreased production of IL-1 receptor antagonist, and increased production ofthe IL-1 receptor antagonist in the presence ofthe test compound indicates that the compound is an agonist of IL-1 receptor antagonist activity. In another preferred embodiment, the causative mutation results in increased production of IL-lα or IL-lβ , and decreased production of IL-lα or IL-lβ in the presence ofthe test compound indicates that the compound is an antagonist of IL- 1 α or IL- 1 β activity. In another embodiment, the invention features transgenic non-human animals and their use in identifying antagonists of IL-lα or IL-lβ activity or agonists of IL-1 Ra activity. Other embodiments and advantages ofthe invention are set forth in the following detailed description and claims. 3. Brief Description of the Figures FIG. 1 shows two different genetic haplotype patterns. FIG. 2 is a graph showing the risk of osteoporotic non-spine fractures. FIG. 3 is a graph showing the risk of osteoporotic hip fractures FIG. 4 is a graph showing the risk of osteoporotic wrist fractures FIG. 5 is a graph showing the risk of non-spine fractures 4. Detailed Description of the Invention 4.1 Definitions For convenience, the meaning of certain terms and phrases employed in the specification, examples, and appended claims is provided below. The term "allele" refers to the different sequence variants found at different polymoφhic regions. For example, IL-IRN (VNTR) has at least five different alleles. The sequence variants may be single or multiple base changes, including without limitation insertions, deletions, or substitutions, or may be a variable number of sequence repeats. The term "allelic pattern" refers to the identity of an allele or alleles at one or more polymoφhic regions. For example, an allelic pattern may consist of a single allele at a polymoφhic site, as for IL-IRN (VNTR) allele 1, which is an allelic pattern having at least one copy of IL-IRN allele 1 at the VNTR ofthe IL-IRN gene loci. Alternatively, an allelic pattern may consist of either a homozygous or heterozygous state at a single polymoφhic site. For example, IL1-RN (VNTR) allele 2,2 is an allelic pattern in which there are two copies ofthe second allele at the VNTR marker of IL-IRN that corresponds to the homozygous IL-RN (VNTR) allele 2 state. Alternatively, an allelic pattern may consist ofthe identity of alleles at more than one polymoφhic site. The term "antibody " as used herein is intended to refer to a binding agent including a whole antibody or a binding fragment thereof which is specifically reactive with an IL-1 polypeptide. Antibodies can be fragmented using conventional techniques and the fragments screened for utility in the same manner as described above for whole antibodies. For example, F(ab)2 fragments can be generated by treating an antibody with pepsin. The resulting F(ab)2 fragment can be treated to reduce disulfide bridges to produce Fab fragments. The antibody ofthe present invention is further intended to include bispecific, single-chain, and chimeric and humanized molecules having affinity for an IL-IB polypeptide conferred by at least one CDR region ofthe antibody. "Biological activity" or "bioactivity" or "activity" or "biological function", which are used interchangeably, for the puφoses herein means an effector or antigenic function that is directly or indirectly performed by an IL-1 polypeptide (whether in its native or denatured conformation), or by any subsequence thereof. Biological activities include binding to a target peptide, e.g., an IL-1 receptor. An IL-1 bioactivity can be modulated by directly affecting an IL-1 polypeptide. Alternatively, an IL-1 bioactivity can be modulated by modulating the level of an IL-1 polypeptide, such as by modulating expression of an IL-1 gene. As used herein the term "bioactive fragment of an IL-1 polypeptide" refers to a fragment of a full-length IL-1 polypeptide, wherein the fragment specifically mimics or antagonizes the activity of a wild-type IL-1 polypeptide. The bioactive fragment preferably is a fragment capable of interacting with an interleukin receptor. The term "an aberrant activity", as applied to an activity of a polypeptide such as IL-1, refers to an activity which differs from the activity ofthe wild-type or native polypeptide or which differs from the activity ofthe polypeptide in a healthy subject. An activity of a polypeptide can be aberrant because it is stronger than the activity of its native counteφart. Alternatively, an activity can be aberrant because it is weaker or absent relative to the activity of its native counteφart. An aberrant activity can also be a change in an activity. For example an aberrant polypeptide can interact with a different target peptide. A cell can have an aberrant IL-1 activity due to overexpression or underexpression of an IL-1 locus gene encoding an IL-1 locus polypeptide. "Cells", "host cells" or "recombinant host cells" are terms used interchangeably herein to refer not only to the particular subject cell, but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact be identical to the parent cell, but are still included within the scope ofthe term as used herein. A "chimera," "mosaic," "chimeric mammal" and the like, refers to a transgenic mammal with a knock-out or knock-in construct in at least some of its genome- containing cells. The terms "control" or "control sample" refer to any sample appropriate to the detection technique employed. The control sample may contain the products ofthe allele detection technique employed or the material to be tested. Further, the controls may be positive or negative controls. By way of example, where the allele detection technique is PCR amplification, followed by size fractionation, the control sample may comprise DNA fragments of an appropriate size. Likewise, where the allele detection technique involves detection of a mutated protein, the control sample may comprise a sample of a mutant protein. However, it is preferred that the control sample comprises the material to be tested. For example, the controls may be a sample of genomic DNA or a cloned portion ofthe IL-1 gene cluster. However, where the sample to be tested is genomic DNA, the control sample is preferably a highly purified sample of genomic DNA. The phrases "disruption ofthe gene" and "targeted disruption" or any similar phrase refers to the site specific interruption of a native DNA sequence so as to prevent expression of that gene in the cell as compared to the wild-type copy ofthe gene. The interruption may be caused by deletions, insertions or modifications to the gene, or any combination thereof. The term "haplotype" as used herein is intended to refer to a set of alleles that are inherited together as a group (are in linkage disequilibrium) at statistically significant levels (p corτ < 0.05). As used herein, the phrase "an IL-1 haplotype" refers to a haplotype in the IL-1 loci. An IL-1 inflammatory or proinflammatory haplotype refers to a haplotype that is indicative of increased agonist and/or decreased antagonist activities. The terms "IL-1 gene cluster" and "IL-1 loci" as used herein include all the nucleic acid at or near the 2ql3 region of chromosome 2, including at least the IL-1 A, IL- IB and IL-IRN genes and any other linked sequences. (Nicklin et al., Genomics 19: 382- 84, 1994). The terms "IL-1A", "IL-IB", and "IL-IRN" as used herein refer to the genes coding for IL-1 , IL-1 , and IL-1 receptor antagonist, respectively. The gene accession number for IL-1 A, IL-IB, and IL-IRN are X03833, X04500, and X64532, respectively. "IL-1 functional mutation" refers to a mutation within the IL-1 gene cluster that results in an altered phenotype (i.e. effects the function of an IL-1 gene or protein). Examples include: IL-lA(+4845) allele 2, IL-IB (+3954) allele 2, IL-IB (+6912) allele 2 and IL-IRN (+2018) allele 2. "IL-1X (Z) allele Y " refers to a particular allelic form, designated Y, occurring at an IL-1 locus polymoφhic site in gene X, wherein X is IL-1 A, B, or RN and positioned at or near nucleotide Z, wherein nucleotide Z is numbered relative to the major transcriptional start site, which is nucleotide +1, ofthe particular IL-1 gene X. As further used herein, the term "IL-1X allele (Z)" refers to all alleles of an IL-1 polymoφhic site in gene X positioned at or near nucleotide Z. For example, the term "IL-IRN (+2018) allele" refers to alternative forms ofthe IL-IRN gene at marker +2018. "IL-IRN (+2018) allele 1" refers to a form ofthe IL-IRN gene which contains a cytosine (C) at position +2018 ofthe sense strand. Clay et al, Hum. Genet. 97:723-26, 1996. "IL-IRN (+2018) allele 2" refers to a form ofthe IL-IRN gene which contains a thymine (T) at position +2018 ofthe plus strand. When a subject has two identical IL-IRN alleles, the subject is said to be homozygous, or to have the homozygous state. When a subject has two different IL-IRN alleles, the subject is said to be heterozygous, or to have the heterozygous state. The term "IL-IRN (+2018) allele 2,2" refers to the homozygous IL-1 RN (+2018) allele 2 state. Conversely, the term "IL-IRN (+2018) allele 1,1" refers to the homozygous IL-1 RN (+2018) allele 1 state. The term "IL-IRN (+2018) allele 1,2" refers to the heterozygous allele 1 and 2 state. "IL-1 related" as used herein is meant to include all genes related to the human IL-1 locus genes on human chromosome 2 (2q 12-14). These include IL-1 genes of the human IL-1 gene cluster located at chromosome 2 (2q 13-14) which include: the IL-IA gene which encodes interleukin-lα, the IL-IB gene which encodes interleukin-lβ, and the IL-IRN (or IL-lra) gene which encodes the interleukin-1 receptor antagonist. Furthermore these IL-1 related genes include the type I and type II human IL-1 receptor genes located on human chromosome 2 (2ql2) and their mouse homo logs located on mouse chromosome 1 at position 19.5 cM. Interleukin-lα, interleukin-lβ, and interleukin-1 RN are related in so much as they all bind to IL-1 type I receptors, however only interleukin-lα and interleukin- lβ are agonist ligands which activate IL-1 type I receptors, while interleukin-1 RN is a naturally occurring antagonist ligand. Where the term "IL-1" is used in reference to a gene product or polypeptide, it is meant to refer to all gene products encoded by the interleukin-1 locus on human chromosome 2 (2q 12-14) and their corresponding homo logs from other species or functional variants thereof. The term IL-1 thus includes secreted polypeptides which promote an inflammatory response, such as IL-lα and IL-1 β, as well as a secreted polypeptide which antagonize inflammatory responses, such as IL-1 receptor antagonist and the IL-1 type II (decoy) receptor. An "IL-1 receptor" or "IL-1R" refers to various cell membrane bound protein receptors capable of binding to and/or transducing a signal from an IL-1 locus- encoded ligand. The term applies to any ofthe proteins which are capable of binding interleukin-1 (IL-1) molecules and, in their native configuration as mammalian plasma membrane proteins, presumably play a role in transducing the signal provided by IL-1 to a cell. As used herein, the term includes analogs of native proteins with IL-1 -binding or signal transducing activity. Examples include the human and murine IL-1 receptors described in U.S. Patent No. 4,968,607. The term "IL-1 nucleic acid" refers to a nucleic acid encoding an IL-1 protein. An "IL-1 polypeptide" and "IL-1 protein" are intended to encompass polypeptides comprising the amino acid sequence encoded by the IL-1 genomic DNA sequences shown in Figures 1, 2, and 3, or fragments thereof, and homo logs thereof and include agonist and antagonist polypeptides. "Increased risk" refers to a statistically higher frequency of occurrence ofthe disease or condition in an individual carrying a particular polymoφhic allele in comparison to the frequency of occurrence ofthe disease or condition in a member of a population that does not carry the particular polymoφhic allele. The term "interact" as used herein is meant to include detectable relationships or associations (e.g. biochemical interactions) between molecules, such as interactions between protein-protein, protein-nucleic acid, nucleic acid-nucleic acid and protein-small molecule or nucleic acid-small molecule in nature. The term "isolated" as used herein with respect to nucleic acids, such as DNA or RNA, refers to molecules separated from other DNAs, or RNAs, respectively, that are present in the natural source ofthe macromolecule. For example, an isolated nucleic acid encoding one ofthe subject IL-1 polypeptides preferably includes no more than 10 kilobases (kb) of nucleic acid sequence which naturally immediately flanks the IL-1 gene in genomic DNA, more preferably no more than 5kb of such naturally occurring flanking sequences, and most preferably less than 1.5kb of such naturally occurring flanking sequence. The term isolated as used herein also refers to a nucleic acid or peptide that is substantially free of cellular material, viral material, or culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized. Moreover, an "isolated nucleic acid" is meant to include nucleic acid fragments which are not naturally occurring as fragments and would not be found in the natural state. The term "isolated" is also used herein to refer to polypeptides which are isolated from other cellular proteins and is meant to encompass both purified and recombinant polypeptides. A "knock-in" transgenic animal refers to an animal that has had a modified gene introduced into its genome and the modified gene can be of exogenous or endogenous origin. A "knock-out " transgenic animal refers to an animal in which there is partial or complete suppression ofthe expression of an endogenous gene (e.g, based on deletion of at least a portion ofthe gene, replacement of at least a portion ofthe gene with a second sequence, introduction of stop codons, the mutation of bases encoding critical amino acids, or the removal of an intron junction, etc.). A "knock-out construct" refers to a nucleic acid sequence that can be used to decrease or suppress expression of a protein encoded by endogenous DNA sequences in a cell. In a simple example, the knock-out construct is comprised of a gene, such as the IL-IRN gene, with a deletion in a critical portion ofthe gene, so that active protein cannot be expressed therefrom. Alternatively, a number of termination codons can be added to the native gene to cause early termination ofthe protein or an intron junction can be inactivated. In a typical knock-out construct, some portion ofthe gene is replaced with a selectable marker (such as the neo gene) so that the gene can be represented as follows: IL-IRN 57neo/ IL-IRN 3', where IL-1RN5' and IL-IRN 3', refer to genomic or cDNA sequences which are, respectively, upstream and downstream relative to a portion ofthe IL- IRN gene and where neo refers to a neomycin resistance gene. In another knock-out construct, a second selectable marker is added in a flanking position so that the gene can be represented as: IL-lRN/neo/IL-lRN/TK, where TK is a thymidine kinase gene which can be added to either the IL-1RN5' or the IL-1RN3' sequence ofthe preceding construct and which further can be selected against (i.e. is a negative selectable marker) in appropriate media. This two-marker construct allows the selection of homologous recombination events, which removes the flanking TK marker, from non-homologous recombination events which typically retain the TK sequences. The gene deletion and/or replacement can be from the exons, introns, especially intron junctions, and/or the regulatory regions such as promoters. "Linkage disequilibrium" refers to co-inheritance of two alleles at frequencies greater than would be expected from the separate frequencies of occurrence of each allele in a given control population. The expected frequency of occurrence of two alleles that are inherited independently is the frequency ofthe first allele multiplied by the frequency ofthe second allele. Alleles that co-occur at expected frequencies are said to be in "linkage disequilibrium". The cause of linkage disequilibrium is often unclear. It can be due to selection for certain allele combinations or to recent admixture of genetically heterogeneous populations. In addition, in the case of markers that are very tightly linked to a disease gene, an association of an allele (or group of linked alleles) with the disease gene is expected if the disease mutation occurred in the recent past, so that sufficient time has not elapsed for equilibrium to be achieved through recombination events in the specific chromosomal region. When referring to allelic patterns that are comprised of more than one allele, a first allelic pattern is in linkage disequilibrium with a second allelic pattern if all the alleles that comprise the first allelic pattern are in linkage disequilibrium with at least one ofthe alleles ofthe second allelic pattern. An example of linkage disequilibrium is that which occurs between the alleles at the IL-IRN (+2018) and IL-IRN (VNTR) polymoφhic sites. The two alleles at IL-IRN (+2018) are 100% in linkage disequilibrium with the two most frequent alleles of IL-IRN (VNTR), which are allele 1 and allele 2. The term "marker" refers to a sequence in the genome that is known to vary among individuals. For example, the IL-IRN gene has a marker that consists of a variable number of tandem repeats (VNTR). A "mutated gene" or "mutation" or "functional mutation" refers to an allelic form of a gene, which is capable of altering the phenotype of a subject having the mutated gene relative to a subject which does not have the mutated gene. The altered phenotype caused by a mutation can be corrected or compensated for by certain agents. If a subject must be homozygous for this mutation to have an altered phenotype, the mutation is said to be recessive. If one copy ofthe mutated gene is sufficient to alter the phenotype ofthe subject, the mutation is said to be dominant. If a subject has one copy ofthe mutated gene and has a phenotype that is intermediate between that of a homozygous and that of a heterozygous subject (for that gene), the mutation is said to be co-dominant. A "non-human animal" ofthe invention includes mammals such as rodents, non-human primates, sheep, dogs, cows, goats, etc. amphibians, such a s members of the Xenopus genus, and transgenic avians (e.g. chickens, birds, etc.). The term "chimeric animal" is used herein to refer to animals in which the recombinant gene is found, or in which the recombinant gene is expressed in some but not all cells ofthe animal. The term "tissue-specific chimeric animal" indicates that one ofthe recombinant IL-1 genes is present and/or expressed or disrupted in some tissues but not others. The term "non-human mammal" refers to any member ofthe class Mammalia, except for humans. As used herein, the term "nucleic acid" refers to polynucleotides or oligonucleotides such as deoxyribonucleic acid (DNA), and, where appropriate, ribonucleic acid (RNA). The term should also be understood to include, as equivalents, analogs of either RNA or DNA made from nucleotide analogs (e.g. peptide nucleic acids) and as applicable to the embodiment being described, single (sense or antisense) and double- stranded polynucleotides. The term "osteoporosis" is defined by the World Health Organization as "...a systemic skeletal disease characterized by low bone mass and micro-architectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture"(WHO Consensus Development Conference 1993). The clinical definition of osteoporosis is a condition in which the bone mineral density (BMD) or bone mineral concentration (BMC) is greater than about 2.5 standard deviations (SD) below the mean of young healthy women. Severe osteoporosis is defined as having a BMD or BMC greater than about 2.5 SD below the mean of young healthy women and the presence of one or more fragility fractures. Since bone loss is not strictly confined to specific sites, osteoporosis can manifest itself in various ways including alveolar, femoral, radial, vertebral or wrist bone loss or fracture incidence, postmenopausal bone loss, severely reduced bone mass, fracture incidence or rate of bone loss. The term "polymoφhism" refers to the coexistence of more than one form of a gene or portion (e.g., allelic variant) thereof. A portion of a gene of which there are at least two different forms, i.e., two different nucleotide sequences, is referred to as a "polymoφhic region of a gene". A specific genetic sequence at a polymoφhic region of a gene is an allele. A polymoφhic region can be a single nucleotide, the identity of which differs in different alleles. A polymoφhic region can also be several nucleotides long. The term "propensity to disease," also "predisposition" or "susceptibility" to disease or any similar phrase, means that certain alleles are hereby discovered to be associated with or predictive of a subject's incidence of developing a particular disease (e.g. a vascular disease). The alleles are thus over-represented in frequency in individuals with disease as compared to healthy individuals. Thus, these alleles can be used to predict disease even in pre-symptomatic or pre-diseased individuals. "Small molecule" as used herein, is meant to refer to a composition, which has a molecular weight of less than about 5kD and most preferably less than about 4kD. Small molecules can be nucleic acids, peptides, peptidomimetics, carbohydrates, lipids or other organic or inorganic molecules. As used herein, the term "specifically hybridizes" or "specifically detects" refers to the ability of a nucleic acid molecule to hybridize to at least approximately 6 consecutive nucleotides of a sample nucleic acid. "Transcriptional regulatory sequence" is a generic term used throughout the specification to refer to DNA sequences, such as initiation signals, enhancers, and promoters, which induce or control transcription of protein coding sequences with which they are operably linked. As used herein, the term "transgene" means a nucleic acid sequence (encoding, e.g., one ofthe IL-1 polypeptides, or an antisense transcript thereto) which has been introduced into a cell. A transgene could be partly or entirely heterologous, i.e., foreign, to the transgenic animal or cell into which it is introduced, or, is homologous to an endogenous gene ofthe transgenic animal or cell into which it is introduced, but which is designed to be inserted, or is inserted, into the animal's genome in such a way as to alter the genome ofthe cell into which it is inserted (e.g., it is inserted at a location which differs from that ofthe natural gene or its insertion results in a knockout). A transgene can also be present in a cell in the form of an episome. A transgene can include one or more transcriptional regulatory sequences and any other nucleic acid, such as introns, that may be necessary for optimal expression of a selected nucleic acid. A "transgenic animal" refers to any animal, preferably a non-human mammal, bird or an amphibian, in which one or more ofthe cells ofthe animal contain heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor ofthe cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or in vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule. This molecule may be integrated within a chromosome, or it may be extrachromosomally replicating DNA. In the typical transgenic animals described herein, the transgene causes cells to express a recombinant form of one of an IL-1 polypeptide, e.g. either agonistic or antagonistic forms. However, transgenic animals in which the recombinant gene is silent are also contemplated, as for example, the FLP or CRE recombinase dependent constructs described below. Moreover, "transgenic animal" also includes those recombinant animals in which gene disruption of one or more genes is caused by human intervention, including both recombination and antisense techniques. The term is intended to include all progeny generations. Thus, the founder animal and all FI, F2, F3, and so on, progeny thereof are included. The term "treating" as used herein is intended to encompass curing as well as ameliorating at least one symptom of a condition or disease. The term "vector" refers to a nucleic acid molecule, which is capable of transporting another nucleic acid to which it has been linked. One type of preferred vector is an episome, i.e., a nucleic acid capable of extra-chromosomal replication. Preferred vectors are those capable of autonomous replication and/or expression of nucleic acids to which they are linked. Vectors capable of directing the expression of genes to which they are operatively linked are referred to herein as "expression vectors". In general, expression vectors of utility in recombinant DNA techniques are often in the form of "plasmids" which refer generally to circular double stranded DNA loops which, in their vector form are not bound to the chromosome. In the present specification, "plasmid" and "vector" are used interchangeably as the plasmid is the most commonly used form of vector. However, the invention is intended to include such other forms of expression vectors which serve equivalent functions and which become known in the art subsequently hereto. The term "wild-type allele" refers to an allele of a gene which, when present in two copies in a subject results in a wild-type phenotype. There can be several different wild-type alleles of a specific gene, since certain nucleotide changes in a gene may not affect the phenotype of a subject having two copies ofthe gene with the nucleotide changes. 4.2 Predictive Medicine 4.2.1. Identifying IL-2 Alleles and Haplotypes The present invention is based at least in part, on the identification of certain alleles that have been determined to be association (to a statistically significant extent) to bone loss, fracture risk or other indicators of osteoporosis. Therefore, detection ofthe alleles can indicate that the subject has or is predisposed to the development of osteoporosis. However, because these alleles are in linkage disequilibrium with other alleles, the detection of such other linked alleles can also indicate that the subject has or is predisposed to the development of a particular disease or condition. For example, the 44112332 haplotype comprises the following genotype: allele 4 ofthe 222/223 marker of IL-IA allele 4 ofthe gz5/gz6 marker of IL-IA allele 1 ofthe -889 marker of IL-IA allele 1 ofthe +3954 marker of IL-IB allele 2 of the -511 marker of IL- 1 B allele 3 ofthe gaat.p33330 marker allele 3 ofthe Y31 marker allele 2 of +2018 of IL-IRN allele 2 ofthe VNTR marker of IL-1 R Three other polymoφhisms in an IL-IRN alternative exon (Exon lie, which produces an intracellular form ofthe gene product) are also in linkage disequilibrium with allele 2 of IL-IRN (VNTR) (Clay et al., (1996) Hum Genet 97:723-26). These include: IL- IRN exon lie (1812) (GenBank:X77090 at 1812); the IL-IRN exon lie (1868) polymoφhism (GenBank:X77090 at 1868); and the IL-IRN exon lie (1887) polymoφhism (GenBank:X77090 at 1887). Furthermore yet another polymoφhism in the promoter for the alternatively spliced intracellular form ofthe gene, the Pic (1731) polymoφhism (GenBank:X77090 at 1731), is also in linkage disequilibrium with allele 2 of the IL-IRN (VNTR) polymoφhic locus. For each of these polymoφhic loci, the allele 2 sequence variant has been determined to be in linkage disequilibrium with allele 2 ofthe IL-IRN (VNTR) locus (Clay et al., (1996) Hum Genet 97:723-26). The 33221461 haplotype comprises the following genotype: allele 3 ofthe 222/223 marker of IL-IA allele 3 ofthe gz5/gz6 marker of IL-IA allele 2 ofthe -889 marker of IL-IA allele 2 ofthe +3954 marker of IL-IB allele 1 ofthe -511 marker of IL-IB allele 4 ofthe gaat.p33330 marker allele 6 ofthe Y31 marker allele 1 of +2018 of IL-IRN allele 1 of the VNTR marker of IL-IRN Individuals with the 44112332 haplotype are typically oveφroducers of both IL-lα and IL-lβ proteins, upon stimulation. In contrast, individuals with the 33221461 haplotype are typically undeφroducers of IL-lra. Each haplotype results in a net IL-lα and IL-lβ proteins, upon stimulation. In contrast, individuals with the 33221461 haplotype are typically undeφroducers of IL-lra. Each haplotype results in a net proinflammatory response. Each allele within a haplotype may have an effect, as well as a composite genotype effect. In addition, particular diseases may be associated with both haplotype patterns. In addition to the allelic patterns described above, as described herein, one of skill in the art can readily identify other alleles (including polymoφhisms and mutations) that are in linkage disequilibrium with an allele associated with osteoporosis. For example, a nucleic acid sample from a first group of subjects without osteoporosis can be collected, as well as DNA from a second group of subjects with the disorder. The nucleic acid sample can then be compared to identify those alleles that are over-represented in the second group as compared with the first group, wherein such alleles are presumably associated with osteoporosis. Alternatively, alleles that are in linkage disequilibrium with an allele that is associated with osteoporosis can be identified, for example, by genotyping a large population and performing statistical analysis to determine which alleles appear more commonly together than expected. Preferably the group is chosen to be comprised of genetically related individuals. Genetically related individuals include individuals from the same race, the same ethnic group, or even the same family. As the degree of genetic relatedness between a control group and a test group increases, so does the predictive value of polymoφhic alleles which are ever more distantly linked to a disease-causing allele. This is because less evolutionary time has passed to allow polymoφhisms which are linked along a chromosome in a founder population to redistribute through genetic cross-over events. Thus race-specific, ethnic-specific, and even family-specific diagnostic genotyping assays can be developed to allow for the detection of disease alleles which arose at ever more recent times in human evolution, e.g., after divergence ofthe major human races, after the separation of human populations into distinct ethnic groups, and even within the recent history of a particular family line. Linkage disequilibrium between two polymoφhic markers or between one polymoφhic marker and a disease-causing mutation is a meta-stable state. Absent selective pressure or the sporadic linked reoccurrence ofthe underlying mutational events, the polymoφhisms will eventually become disassociated by chromosomal recombination events and will thereby reach linkage equilibrium through the course of human evolution. Thus, the likelihood of finding a polymoφhic allele in linkage disequilibrium with a disease or condition may increase with changes in at least two factors: decreasing physical distance between the polymoφhic marker and the disease-causing mutation, and decreasing number of meiotic generations available for the dissociation ofthe linked pair. Consideration ofthe latter factor suggests that, the more closely related two individuals are, the more likely they will share a common parental chromosome or chromosomal region containing the linked polymoφhisms and the less likely that this linked pair will have become unlinked through meiotic cross-over events occurring each generation. As a result, the more closely related two individuals are, the more likely it is that widely spaced polymoφhisms may be co-inherited. Thus, for individuals related by common race, ethnicity or family, the reliability of ever more distantly spaced polymoφhic loci can be relied upon as an indicator of inheritance of a linked disease-causing mutation. Appropriate probes may be designed to hybridize to a specific gene ofthe IL-1 locus, such as IL-IA, IL-IB or IL-IRN or a related gene. These genomic DNA sequences are shown in Figures 3, 4 and 5, respectively, and further correspond to SEQ ID Nos. 1, 2 and 3, respectively. Alternatively, these probes may incoφorate other regions of the relevant genomic locus, including intergenic sequences. Indeed the IL-1 region of human chromosome 2 spans some 400,000 base pairs and, assuming an average of one single nucleotide polymoφhism every 1,000 base pairs, includes some 400 SNPs loci alone. Yet other polymoφhisms available for use with the immediate invention are obtainable from various public sources. For example, the human genome database collects intragenic SNPs, is searchable by sequence and currently contains approximately 2,700 entries (http://hgbase.interactiva.de). Also available is a human polymoφhism database maintained by the Massachusetts Institute of Technology (MIT SNP database (http://www.genome.wi.mit.edu/SNP/human/index.html)). From such sources SNPs as well as other human polymoφhisms may be found. For example, examination ofthe IL-1 region ofthe human genome in any one of these databases reveals that the IL-1 locus genes are flanked by a centromere proximal polymoφhic marker designated microsatellite marker AFM220ze3 at 127.4 cM (centiMorgans) (see GenBank Ace. No. Z17008) and a distal polymoφhic marker designated microsatellite anchor marker AFM087xal at 127.9 cM (see GenBank Ace. No. Z16545). These human polymoφhic loci are both CA dinucleotide repeat microsatellite polymoφhisms, and, as such, show a high degree of heterozygosity in human populations. For example, one allele of AFM220ze3 generates a 211 bp PCR amplification product with a 5' primer ofthe sequence TGTACCTAAGCCCACCCTTTAGAGC (SEQ ID No. 4) and a 3' primer ofthe sequence TGGCCTCCAGAAACCTCCAA (SEQ ID No. 5). Furthermore, one allele of AFM087xal generates a 177 bp PCR amplification product with a 5' primer of the sequence GCTGATATTCTGGTGGGAAA (SEQ ID No. 6) and a 3* primer of the sequence GGCAAGAGCAAAACTCTGTC (SEQ ID No. 7). Equivalent primers corresponding to unique sequences occurring 5' and 3' to these human chromosome 2 CA dinucleotide repeat polymoφhisms will be apparent to one of skill in the art. Reasonable equivalent primers include those which hybridize within about 1 kb ofthe designated primer, and which further are anywhere from about 17 bp to about 27 bp in length. A general guideline for designing primers for amplification of unique human chromosomal genomic sequences is that they possess a melting temperature of at least about 50°C, wherein an approximate melting temperature can be estimated using the formula T melt = [2 x (# of A or T) + 4 x (# of G or C)]. A number of other human polymoφhic loci occur between these two CA dinucleotide repeat polymoφhisms and provide additional targets for determination of a prognostic allele in a family or other group of genetically related individuals. For example, the National Center for Biotechnology Information web site (www.ncbi.nlm.nih.gov/genemap/) lists a number of polymoφhism markers in the region ofthe IL-1 locus and provides guidance in designing appropriate primers for amplification and analysis of these markers. Accordingly, the nucleotide segments ofthe invention may be used for their ability to selectively form duplex molecules with complementary stretches of human chromosome 2 q 12-13 or cDNAs from that region or to provide primers for amplification of DNA or cDNA from this region. The design of appropriate probes for this puφose requires consideration of a number of factors. For example, fragments having a length of between 10, 15, or 18 nucleotides to about 20, or to about 30 nucleotides, will find particular utility. Longer sequences, e.g., 40, 50, 80, 90, 100, even up to full length, are even more preferred for certain embodiments. Lengths of oligonucleotides of at least about 18 to 20 nucleotides are well accepted by those of skill in the art as sufficient to allow sufficiently specific hybridization so as to be useful as a molecular probe. Furthermore, depending on the application envisioned, one will desire to employ varying conditions of hybridization to achieve varying degrees of selectivity of probe towards target sequence. For applications requiring high selectivity, one will typically desire to employ relatively stringent conditions to form the hybrids. For example, relatively low salt and/or high temperature conditions, such as provided by 0.02 M-0.15M NaCl at temperatures of about 50 ° C to about 70° C. Such selective conditions may tolerate little, if any, mismatch between the probe and the template or target strand. Other alleles or other indicia of a disorder can be detected or monitored in a subject in conjunction with detection ofthe alleles described above, for example, identifying vessel wall thickness (e.g. as measured by ultrasound), or whether the subject smokes, drinks is overweight, is under stress or exercises. 4.2.2 Detection of Alleles Many methods are available for detecting specific alleles at human polymoφhic loci. The preferred method for detecting a specific polymoφhic allele will depend, in part, upon the molecular nature ofthe polymoφhism. For example, the various allelic forms ofthe polymoφhic locus may differ by a single base-pair ofthe DNA. Such single nucleotide polymoφhisms (or SNPs) are major contributors to genetic variation, comprising some 80% of all known polymoφhisms, and their density in the human genome is estimated to be on average 1 per 1,000 base pairs. SNPs are most frequently biallelic- occurring in only two different forms (although up to four different forms of an SNP, corresponding to the four different nucleotide bases occurring in DNA, are theoretically possible). Nevertheless, SNPs are mutationally more stable than other polymoφhisms, making them suitable for association studies in which linkage disequilibrium between markers and an unknown variant is used to map disease-causing mutations. In addition, because SNPs typically have only two alleles, they can be genotyped by a simple plus/minus assay rather than a length measurement, making them more amenable to automation. A variety of methods are available for detecting the presence of a particular single nucleotide polymoφhic allele in an individual. Advancements in this field have provided accurate, easy, and inexpensive large-scale SNP genotyping. Most recently, for example, several new techniques have been described including dynamic allele-specific hybridization (DASH), microplate array diagonal gel electrophoresis (MADGE), pyrosequencing, oligonucleotide-specific ligation, the TaqMan system as well as various DNA "chip" technologies such as the Affymetrix SNP chips. These methods require amplification ofthe target genetic region, typically by PCR. Still other newly developed methods, based on the generation of small signal molecules by invasive cleavage followed by mass spectrometry or immobilized padlock probes and rolling-circle amplification, might eventually eliminate the need for PCR. Several ofthe methods known in the art for detecting specific single nucleotide polymoφhisms are summarized below. The method of the present invention is understood to include all available methods. Several methods have been developed to facilitate analysis of single nucleotide polymoφhisms. In one embodiment, the single base polymoφhism can be detected by using a specialized exonuclease-resistant nucleotide, as disclosed, e.g., in Mundy, C. R. (U.S. Pat. No.4,656,127). According to the method, a primer complementary to the allelic sequence immediately 3' to the polymoφhic site is permitted to hybridize to a target molecule obtained from a particular animal or human. If the polymoφhic site on the target molecule contains a nucleotide that is complementary to the particular exonuclease-resistant nucleotide derivative present, then that derivative will be incoφorated onto the end ofthe hybridized primer. Such incoφoration renders the primer resistant to exonuclease, and thereby permits its detection. Since the identity ofthe exonuclease-resistant derivative ofthe sample is known, a finding that the primer has become resistant to exonucleases reveals that the nucleotide present in the polymoφhic site ofthe target molecule was complementary to that ofthe nucleotide derivative used in the reaction. This method has the advantage that it does not require the determination of large amounts of extraneous sequence data. In another embodiment ofthe invention, a solution-based method is used for determining the identity ofthe nucleotide of a polymoφhic site. Cohen, D. et al. (French Patent 2,650,840; PCT Appln. No. WO91/02087). As in the Mundy method of U.S. Pat. No. 4,656,127, a primer is employed that is complementary to allelic sequences immediately 3' to a polymoφhic site. The method determines the identity ofthe nucleotide of that site using labeled dideoxynucleotide derivatives, which, if complementary to the nucleotide ofthe polymoφhic site will become incoφorated onto the terminus ofthe primer. An alternative method, known as Genetic Bit Analysis or GBA ™ is described by Goelet, P. et al. (PCT Appln. No. 92/15712). The method of Goelet, P. et al. uses mixtures of labeled terminators and a primer that is complementary to the sequence 3' to a polymoφhic site. The labeled terminator that is incoφorated is thus determined by, and complementary to, the nucleotide present in the polymoφhic site ofthe target molecule being evaluated. In contrast to the method of Cohen et al. (French Patent 2,650,840; PCT Appln. No. WO91/02087) the method of Goelet, P. et al. is preferably a heterogeneous phase assay, in which the primer or the target molecule is immobilized to a solid phase. Recently, several primer-guided nucleotide incoφoration procedures for assaying polymoφhic sites in DNA have been described (Komher, J. S. et al., Nucl. Acids. Res. 17:7779-7784 (1989); Sokolov, B. P., Nucl. Acids Res. 18:3671 (1990); Syvanen, A. -C, et al., Genomics 8:684-692 (1990); Kuppuswamy, M. N. et al., Proc. Natl. Acad. Sci. (U.S.A.) 88:1143-1147 (1991); Prezant, T. R. et al., Hum. Mutat. 1:159-164 (1992); Ugozzoli, L. et al., GATA 9:107-112 (1992); Nyren, P. et al., Anal. Biochem. 208:171-175 (1993)). These methods differ from GBA ™ in that they all rely on the incoφoration of labeled deoxynucleotides to discriminate between bases at a polymoφhic site. In such a format, since the signal is proportional to the number of deoxynucleotides incoφorated, polymoφhisms that occur in runs ofthe same nucleotide can result in signals that are proportional to the length ofthe run (Syvanen, A. -C, et al., Amer. J. Hum. Genet. 52:46-59 (1993)). For mutations that produce premature termination of protein translation, the protein truncation test (PTT) offers an efficient diagnostic approach (Roest, et. al., (1993) Hum. Mol. Genet. 2:1719-21; van der Luijt, et. al., (1994) Genomics 20:1-4). For PTT, RNA is initially isolated from available tissue and reverse-transcribed, and the segment of interest is amplified by PCR. The products of reverse transcription PCR are then used as a template for nested PCR amplification with a primer that contains an RNA polymerase promoter and a sequence for initiating eukaryotic translation. After amplification ofthe region of interest, the unique motifs incoφorated into the primer permit sequential in vitro transcription and translation ofthe PCR products. Upon sodium dodecyl sulfate- polyacrylamide gel electrophoresis of translation products, the appearance of truncated polypeptides signals the presence of a mutation that causes premature termination of translation. In a variation of this technique, DNA (as opposed to RNA) is used as a PCR template when the target region of interest is derived from a single exon. Any cell type or tissue may be utilized to obtain nucleic acid samples for use in the diagnostics described herein. In a preferred embodiment, the DNA sample is obtained from a bodily fluid, e.g, blood, obtained by known techniques (e.g. venipuncture) or saliva. Alternatively, nucleic acid tests can be performed on dry samples (e.g. hair or skin). When using RNA or protein, the cells or tissues that may be utilized must express an IL-1 gene. Diagnostic procedures may also be performed in situ directly upon tissue sections (fixed and/or frozen) of patient tissue obtained from biopsies or resections, such that no nucleic acid purification is necessary. Nucleic acid reagents may be used as probes and/or primers for such in situ procedures (see, for example, Nuovo, G.J., 1992, PCR in situ hybridization: protocols and applications, Raven Press, NY). In addition to methods which focus primarily on the detection of one nucleic acid sequence, profiles may also be assessed in such detection schemes. Fingeφrint profiles may be generated, for example, by utilizing a differential display procedure, Northern analysis and/or RT-PCR. A preferred detection method is allele specific hybridization using probes overlapping a region of at least one allele of an IL-1 proinflammatory haplotype and having about 5, 10, 20, 25, or 30 nucleotides around the mutation or polymoφhic region. In a preferred embodiment ofthe invention, several probes capable of hybridizing specifically to other allelic variants involved in a restenosis are attached to a solid phase support, e.g., a "chip" (which can hold up to about 250,000 oligonucleotides). Oligonucleotides can be bound to a solid support by a variety of processes, including lithography. Mutation detection analysis using these chips comprising oligonucleotides, also termed "DNA probe arrays" is described e.g., in Cronin et al. (1996) Human Mutation 7:244. In one embodiment, a chip comprises all the allelic variants of at least one polymoφhic region of a gene. The solid phase support is then contacted with a test nucleic acid and hybridization to the specific probes is detected. Accordingly, the identity of numerous allelic variants of one or more genes can be identified in a simple hybridization experiment. These techniques may also comprise the step of amplifying the nucleic acid before analysis. Amplification techniques are known to those of skill in the art and include, but are not limited to cloning, polymerase chain reaction (PCR), polymerase chain reaction of specific alleles (ASA), ligase chain reaction (LCR), nested polymerase chain reaction, self sustained sequence replication (Guatelli, J.C. et al., 1990, Proc. Natl. Acad. Sci. USA 87:1874-1878), transcriptional amplification system (Kwoh, D.Y. et al., 1989, Proc. Natl. Acad. Sci. USA 86:1173-1177), and Q- Beta Replicase (Lizardi, P.M. et al., 1988, Bio/Technology 6:1197). Amplification products may be assayed in a variety of ways, including size analysis, restriction digestion followed by size analysis, detecting specific tagged oligonucleotide primers in the reaction products, allele-specific oligonucleotide (ASO) hybridization, allele specific 5' exonuclease detection, sequencing, hybridization, and the like. PCR based detection means can include multiplex amplification of a plurality of markers simultaneously. For example, it is well known in the art to select PCR primers to generate PCR products that do not overlap in size and can be analyzed simultaneously. Alternatively, it is possible to amplify different markers with primers that are differentially labeled and thus can each be differentially detected. Of course, hybridization based detection means allow the differential detection of multiple PCR products in a sample. Other techniques are known in the art to allow multiplex analyses of a plurality of markers. In a merely illustrative embodiment, the method includes the steps of (i) collecting a sample of cells from a patient, (ii) isolating nucleic acid (e.g., genomic, mRNA or both) from the cells ofthe sample, (iii) contacting the nucleic acid sample with one or more primers which specifically hybridize 5' and 3' to at least one allele of an IL-1 proinflammatory haplotype under conditions such that hybridization and amplification of the allele occurs, and (iv) detecting the amplification product. These detection schemes are especially useful for the detection of nucleic acid molecules if such molecules are present in very low numbers. In a preferred embodiment ofthe subject assay, the allele of an IL-1 proinflammatory haplotype is identified by alterations in restriction enzyme cleavage patterns. For example, sample and control DNA is isolated, amplified (optionally), digested with one or more restriction endonucleases, and fragment length sizes are determined by gel electrophoresis. In yet another embodiment, any of a variety of sequencing reactions known in the art can be used to directly sequence the allele. Exemplary sequencing reactions include those based on techniques developed by Maxim and Gilbert ((1977) Proc. Natl Acad Sci USA 74:560) or Sanger (Sanger et al (1977) Proc. Nat. Acad. Sci USA 74:5463). It is also contemplated that any of a variety of automated sequencing procedures may be utilized when performing the subject assays (see, for example Biotechniques (1995) 19:448), including sequencing by mass spectrometry (see, for example PCT publication WO 94/16101; Cohen et al. (1996) Adv Chromatogr 36:127-162; and Griffin et al. (1993) Appl Biochem Biotechnol 38:147-159). It will be evident to one of skill in the art that, for certain embodiments, the occurrence of only one, two or three ofthe nucleic acid bases need be determined in the sequencing reaction. For instance, A-track or the like, e.g., where only one nucleic acid is detected, can be carried out. In a further embodiment, protection from cleavage agents (such as a nuclease, hydroxylamine or osmium tetroxide and with piperidine) can be used to detect mismatched bases in RNA/RNA or RNA/DNA or DNA/DNA heteroduplexes (Myers, et al. (1985) Science 230:1242). In general, the art technique of "mismatch cleavage" starts by providing heteroduplexes formed by hybridizing (labeled) RNA or DNA containing the wild-type allele with the sample. The double-stranded duplexes are treated with an agent which cleaves single-stranded regions ofthe duplex such as which will exist due to base pair mismatches between the control and sample strands. For instance, RNA/DNA duplexes can be treated with RNase and DNA/DNA hybrids treated with SI nuclease to enzymatically digest the mismatched regions. In other embodiments, either DNA/DNA or RNA/DNA duplexes can be treated with hydroxylamine or osmium tetroxide and with piperidine in order to digest mismatched regions. After digestion ofthe mismatched regions, the resulting material is then separated by size on denaturing polyacrylamide gels to determine the site of mutation. See, for example, Cotton et al (1988) Proc. Natl Acad Sci USA 85:4397; and Saleeba et al (1992) Methods Enzymol. 217:286-295. In a preferred embodiment, the control DNA or RNA can be labeled for detection. In still another embodiment, the mismatch cleavage reaction employs one or more proteins that recognize mismatched base pairs in double-stranded DNA (so called "DNA mismatch repair" enzymes). For example, the mutY enzyme of E. coli cleaves A at G/A mismatches and the thymidine DNA glycosylase from HeLa cells cleaves T at G/T mismatches (Hsu et al. (1994) Carcinogenesis 15:1657-1662). According to an exemplary embodiment, a probe based on an allele of an IL-1 locus haplotype is hybridized to a cDNA or other DNA product from a test cell(s). The duplex is treated with a DNA mismatch repair enzyme, and the cleavage products, if any, can be detected from electrophoresis protocols or the like. See, for example, U.S. Patent No. 5,459,039. In other embodiments, alterations in electrophoretic mobility will be used to identify an IL-1 locus allele. For example, single strand conformation polymoφhism (SSCP) may be used to detect differences in electrophoretic mobility between mutant and wild type nucleic acids (Orita et al. (1989) Proc Natl. Acad. Sci USA 86:2766, see also Cotton (1993) Mutat Res 285:125-144; and Hayashi (1992) Genet Anal Tech Appl 9:73- 79). Single-stranded DNA fragments of sample and control IL-1 locus alleles are denatured and allowed to renature. The secondary structure of single-stranded nucleic acids varies according to sequence, the resulting alteration in electrophoretic mobility enables the detection of even a single base change. The DNA fragments may be labeled or detected with labeled probes. The sensitivity ofthe assay may be enhanced by using RNA (rather than DNA), in which the secondary structure is more sensitive to a change in sequence. In a preferred embodiment, the subject method utilizes heteroduplex analysis to separate double stranded heteroduplex molecules on the basis of changes in electrophoretic mobility (Keen et al. (1991) Trends Genet 7:5). In yet another embodiment, the movement of alleles in polyacrylamide gels containing a gradient of denaturant is assayed using denaturing gradient gel electrophoresis (DGGE) (Myers et al. (1985) Nature 313:495). When DGGE is used as the method of analysis, DNA will be modified to insure that it does not completely denature, for example by adding a GC clamp of approximately 40 bp of high-melting GC-rich DNA by PCR. In a further embodiment, a temperature gradient is used in place of a denaturing agent gradient to identify differences in the mobility of control and sample DNA (Rosenbaum and Reissner (1987) Biophys Chem 265:12753). Examples of other techniques for detecting alleles include, but are not limited to, selective oligonucleotide hybridization, selective amplification, or selective primer extension. For example, oligonucleotide primers may be prepared in which the known mutation or nucleotide difference (e.g., in allelic variants) is placed centrally and then hybridized to target DNA under conditions which permit hybridization only if a perfect match is found (Saiki et al. (1986) Nature 324:163); Saiki et al (1989) Proc. Natl Acad. Sci USA 86:6230). Such allele specific oligonucleotide hybridization techniques may be used to test one mutation or polymoφhic region per reaction when oligonucleotides are hybridized to PCR amplified target DNA or a number of different mutations or polymoφhic regions when the oligonucleotides are attached to the hybridizing membrane and hybridized with labelled target DNA. Alternatively, allele specific amplification technology which depends on selective PCR amplification may be used in conjunction with the instant invention. Oligonucleotides used as primers for specific amplification may carry the mutation or polymoφhic region of interest in the center ofthe molecule (so that amplification depends on differential hybridization) (Gibbs et al (1989) Nucleic Acids Res. 17:2437-2448) or at the extreme 3' end of one primer where, under appropriate conditions, mismatch can prevent, or reduce polymerase extension (Prossner (1993) Tibtech 11:238. In addition it may be desirable to introduce a novel restriction site in the region ofthe mutation to create cleavage-based detection (Gasparini et al (1992) Mol. Cell Probes 6:1). It is anticipated that in certain embodiments amplification may also be performed using Taq ligase for amplification (Barany (1991) Proc. Natl. Acad. Sci USA 88:189). In such cases, ligation will occur only if there is a perfect match at the 3' end ofthe 5' sequence making it possible to detect the presence of a known mutation at a specific site by looking for the presence or absence of amplification. In another embodiment, identification ofthe allelic variant is carried out using an oligonucleotide ligation assay (OLA), as described, e.g., in U.S. Pat. No. 4,998,617 and in Landegren, U. et al. ((1988) Science 241:1077-1080). The OLA protocol uses two oligonucleotides which are designed to be capable of hybridizing to abutting sequences of a single strand of a target. One ofthe oligonucleotides is linked to a separation marker, e.g,. biotinylated, and the other is detectably labeled. If the precise complementary sequence is found in a target molecule, the oligonucleotides will hybridize such that their termini abut, and create a ligation substrate. Ligation then permits the labeled oligonucleotide to be recovered using avidin, or another biotin ligand. Nickerson, D. A. et al. have described a nucleic acid detection assay that combines attributes of PCR and OLA (Nickerson, D. A. et al. (1990) Proc. Natl. Acad. Sci. USA 87:8923-27). In this method, PCR is used to achieve the exponential amplification of target DNA, which is then detected using OLA. Several techniques based on this OLA method have been developed and can be used to detect alleles of an IL-1 locus haplotype. For example, U.S. Patent No. 5,593,826 discloses an OLA using an oligonucleotide having 3'-amino group and a 5'-phosphorylated oligonucleotide to form a conjugate having a phosphoramidate linkage. In another variation of OLA described in Tobe et al. ((1996) Nucleic Acids Res 24: 3728), OLA combined with PCR permits typing of two alleles in a single microtiter well. By marking each ofthe allele-specific primers with a unique hapten, i.e. digoxigenin and fluorescein, each OLA reaction can be detected by using hapten specific antibodies that are labeled with different enzyme reporters, alkaline phosphatase or horseradish peroxidase. This system permits the detection ofthe two alleles using a high throughput format that leads to the production of two different colors. Another embodiment ofthe invention is directed to kits for detecting a predisposition for developing a restenosis. This kit may contain one or more oligonucleotides, including 5' and 3' oligonucleotides that hybridize 5' and 3' to at least one allele of an IL-1 locus haplotype. PCR amplification oligonucleotides should hybridize between 25 and 2500 base pairs apart, preferably between about 100 and about 500 bases apart, in order to produce a PCR product of convenient size for subsequent analysis. Particularly preferred primers for use in the diagnostic method ofthe invention include SEQ ID Nos. 1-6 The design of additional oligonucleotides for use in the amplification and detection of IL-1 polymoφhic alleles by the method ofthe invention is facilitated by the availability of both updated sequence information from human chromosome 2ql3 - which contains the human IL-1 locus, and updated human polymoφhism information available for this locus. For example, the DNA sequence for the IL-IA, IL-IB and IL-IRN is shown in Figures 1 (GenBank Accession No. X03833), 2 (GenBank Accession No. X04500) and 3 (GenBank Accession No. X64532) respectively. Suitable primers for the detection of a human polymoφhism in these genes can be readily designed using this sequence information and standard techniques known in the art for the design and optimization of primers sequences. Optimal design of such primer sequences can be achieved, for example, by the use of commercially available primer selection programs such as Primer 2.1, Primer 3 or GeneFisher (See also, Nicklin M.H.J., Weith A. Duff G.W., "A Physical Map ofthe Region Encompassing the Human Interleukin-lα, interleukin-lβ, and Interleukin-1 Receptor Antagonist Genes" Genomics 19: 382 (1995); Nothwang H.G., et al. "Molecular Cloning ofthe Interleukin-1 gene Cluster: Construction of an Integrated YAC/PAC Contig and a partial transcriptional Map in the Region of Chromosome 2ql3" Genomics 41 : 370 (1997); Clark, et al. (1986) Nucl. Acids. Res., 14:7897-7914 [published erratum appears in Nucleic Acids Res., 15:868 (1987) and the Genome Database (GDB) project at the URL http://www.gdb.org). For use in a kit, oligonucleotides may be any of a variety of natural and/or synthetic compositions such as synthetic oligonucleotides, restriction fragments, cDNAs, synthetic peptide nucleic acids (PNAs), and the like. The assay kit and method may also employ labeled oligonucleotides to allow ease of identification in the assays. Examples of labels which may be employed include radio-labels, enzymes, fluorescent compounds, streptavidin, avidin, biotin, magnetic moieties, metal binding moieties, antigen or antibody moieties, and the like. The kit may, optionally, also include DNA sampling means. DNA sampling means are well known to one of skill in the art and can include, but not be limited to substrates, such as filter papers, the AmpliCard™ (University of Sheffield, Sheffield, England S10 2JF; Tarlow, JW, et al, J. of Invest. Dermatol. 103:387-389 (1994)) and the like; DNA purification reagents such as Nucleon™ kits, lysis buffers, proteinase solutions and the like; PCR reagents, such as lOx reaction buffers, thermostable polymerase, dNTPs, and the like; and allele detection means such as the Hinfi restriction enzyme, allele specific oligonucleotides, degenerate oligonucleotide primers for nested PCR from dried blood. 4.2.3. Pharmacogenomics Knowledge ofthe particular alleles associated with a susceptibility to developing osteoporosis, alone or in conjunction with information on other genetic defects contributing to the same condition allows a customization ofthe prevention or treatment in accordance with the individual's genetic profile, the goal of "pharmacogenomics". Thus, comparison of an individual's IL-1 profile to the population profile for osteoporosis, permits the selection or design of drugs or other therapeutic regimens that are expected to be safe and efficacious for a particular patient or patient population (i.e., a group of patients having the same genetic alteration). In addition, the ability to target populations expected to show the highest clinical benefit, based on genetic profile can enable: 1) the repositioning of already marketed drugs; 2) the rescue of drug candidates whose clinical development has been discontinued as a result of safety or efficacy limitations, which are patient subgroup- specific; and 3) an accelerated and less costly development for candidate therapeutics and more optimal drug labeling (e.g. since measuring the effect of various doses of an agent on the causative mutation is useful for optimizing effective dose). The treatment of an individual with a particular therapeutic can be monitored by determining protein (e.g. IL-lα, IL-lβ, or IL-lRa), mRNA and/or transcriptional level. Depending on the level detected, the therapeutic regimen can then be maintained or adjusted (increased or decreased in dose). In a preferred embodiment, the effectiveness of treating a subject with an agent comprises the steps of: (i) obtaining a preadministration sample from a subject prior to administration ofthe agent; (ii) detecting the level or amount of a protein, mRNA or genomic DNA in the preadministration sample; (iii) obtaining one or more post-administration samples from the subject; (iv) detecting the level of expression or activity ofthe protein, mRNA or genomic DNA in the post-administration sample; (v) comparing the level of expression or activity ofthe protein, mRNA or genomic DNA in the preadministration sample with the corresponding protein, mRNA or genomic DNA in the postadministration sample, respectively; and (vi) altering the administration ofthe agent to the subject accordingly. Cells of a subject may also be obtained before and after administration of a therapeutic to detect the level of expression of genes other than an IL-1 gene to verify that the therapeutic does not increase or decrease the expression of genes which could be deleterious. This can be done, e.g., by using the method of transcriptional profiling. Thus, mRNA from cells exposed in vivo to a therapeutic and mRNA from the same type of cells that were not exposed to the therapeutic could be reverse transcribed and hybridized to a chip containing DNA from numerous genes, to thereby compare the expression of genes in cells treated and not treated with the therapeutic. 4.3 Osteoporosis Therapeutics Osteoporosis therapeutics refers to any agent or therapeutic regimen (including pharmaceuticals, nutraceuticals and surgical means) that prevents or postpones the development of or alleviates the symptoms of osteoporosis in the subject. The therapeutic can be a polypeptide, peptidomimetic, nucleic acid or other inorganic or organic molecule, preferably a "small molecule" including vitamins, minerals and other nutrients. Preferably the therapeutic can modulate at least one activity of an IL-1 polypeptide, e.g., interaction with a receptor, by mimicking or potentiating (agonizing) or inhibiting (antagonizing) the effects of a naturally-occurring polypeptide. An agonist can be a wild- type protein or derivative thereof having at least one bioactivity ofthe wild-type, e.g., receptor binding activity. An agonist can also be a compound that upregulates expression of a gene or which increases at least one bioactivity of a protein. An agonist can also be a compound which increases the interaction of a polypeptide with another molecule, e.g., a receptor. An antagonist can be a compound which inhibits or decreases the interaction between a protein and another molecule, e.g., a receptor or an agent that blocks signal transduction or post-translation processing (e.g., IL-1 converting enzyme (ICE) inhibitor). Accordingly, a preferred antagonist is a compound which inhibits or decreases binding to a receptor and thereby blocks subsequent activation ofthe receptor. An antagonist can also be a compound that downregulates expression of a gene or which reduces the amount of a protein present. The antagonist can be a dominant negative form of a polypeptide, e.g., a form of a polypeptide which is capable of interacting with a target peptide, e.g., a receptor, but which does not promote the activation ofthe receptor. The antagonist can also be a nucleic acid encoding a dominant negative form of a polypeptide, an antisense nucleic acid, or a ribozyme capable of interacting specifically with an RNA. Yet other antagonists are molecules which bind to a polypeptide and inhibit its action. Such molecules include peptides, e.g., forms of target peptides which do not have biological activity, and which inhibit binding to receptors. Thus, such peptides will bind to the active site of a protein and prevent it from interacting with target peptides. Yet other antagonists include antibodies that specifically interact with an epitope of a molecule, such that binding interferes with the biological function ofthe polypeptide. In yet another preferred embodiment, the antagonist is a small molecule, such as a molecule capable of inhibiting the interaction between a polypeptide and a target receptor. Alternatively, the small molecule can function as an antagonist by interacting with sites other than the receptor binding site. Modulators of IL-1 (e.g. IL-lα, IL-lβ or IL-1 receptor antagonist) or a protein encoded by a gene that is in linkage disequilibrium with an IL-1 gene can comprise any type of compound, including a protein, peptide, peptidomimetic, small molecule, or nucleic acid. Preferred agonists include nucleic acids (e.g. encoding an IL-1 protein or a gene that is up- or down-regulated by an IL-1 protein), proteins (e.g. IL-1 proteins or a protein that is up- or down-regulated thereby) or a small molecule (e.g. that regulates expression or binding of an IL-1 protein). Preferred antagonists, which can be identified, for example, using the assays described herein, include nucleic acids (e.g. single (antisense) or double stranded (triplex) DNA or PNA and ribozymes), protein (e.g. antibodies) and small molecules that act to suppress or inhibit IL-1 transcription and/or protein activity. 4.3.1. Effective Dose Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining The LD50 (the dose lethal to 50% ofthe population) and the Edso (the dose therapeutically effective in 50% ofthe population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Compounds which exhibit large therapeutic indices are preferred. While compounds that exhibit toxic side effects may be used, care should be taken to design a delivery system that targets such compounds to the site of affected tissues in order to minimize potential damage to uninfected cells and, thereby, reduce side effects. The data obtained from the cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method ofthe invention, the therapeutically effective dose can be estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 (i.e., the concentration ofthe test compound which achieves a half-maximal inhibition of symptoms) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography. 4.3.2. Formulation and Use Compositions for use in accordance with the present invention may be formulated in a conventional manner using one or more physiologically acceptable carriers or excipients. Thus, the compounds and their physiologically acceptable salts and solvates may be formulated for administration by, for example, injection, inhalation or insufflation (either through the mouth or the nose) or oral, buccal, parenteral or rectal administration. For such therapy, the compounds ofthe invention can be formulated for a variety of loads of administration, including systemic and topical or localized administration. Techniques and formulations generally may be found in Remmington's Pharmaceutical Sciences, Meade Publishing Co., Easton, PA. For systemic administration, injection is preferred, including intramuscular, intravenous, intraperitoneal, and subcutaneous. For injection, the compounds ofthe invention can be formulated in liquid solutions, preferably in physiologically compatible buffers such as Hank's solution or Ringer's solution. In addition, the compounds may be formulated in solid form and redissolved or suspended immediately prior to use. Lyophilized forms are also included. For oral administration, the compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinised maize starch, polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium hydrogen phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrants (e.g., potato starch or sodium starch glycolate); or wetting agents (e.g., sodium lauryl sulfate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, cellulose derivatives or hydrogenated edible fats); emulsifying agents (e.g., lecithin or acacia); non-aqueous vehicles (e.g., ationd oil, oily esters, ethyl alcohol or fractionated vegetable oils); and preservatives (e.g., methyl or propyl-p-hydroxybenzoates or sorbic acid). The preparations may also contain buffer salts, flavoring, coloring and sweetening agents as appropriate. Preparations for oral administration may be suitably formulated to give controlled release ofthe active compound. For buccal administration the compositions may take the form of tablets or lozenges formulated in conventional manner. For administration by inhalation, the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebuliser, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol the dosage unit may be determined by providing a valve to deliver a metered amount. Capsules and cartridges of e.g., gelatin for use in an inhaler or insufflator may be formulated containing a powder mix ofthe compound and a suitable powder base such as lactose or starch. The compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulating agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use. The compounds may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides. In addition to the formulations described previously, the compounds may also be formulated as a depot preparation. Such long acting formulations may be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection. Thus, for example, the compounds may be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt. Other suitable delivery systems include microspheres which offer the possibility of local noninvasive delivery of drugs over an extended period of time. This technology utilizes microspheres of precapillary size which can be injected via a coronary catheter into any selected part ofthe e.g. heart or other organs without causing inflammation or ischemia. The administered therapeutic is slowly released from these microspheres and taken up by surrounding tissue cells (e.g. endothelial cells). Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, for transmucosal administration bile salts and fusidic acid derivatives. In addition, detergents may be used to facilitate permeation. Transmucosal administration may be through nasal sprays or using suppositories. For topical administration, the oligomers ofthe invention are formulated into ointments, salves, gels, or creams as generally known in the art. A wash solution can be used locally to treat an injury or inflammation to accelerate healing. The compositions may, if desired, be presented in a pack or dispenser device which may contain one or more unit dosage forms containing the active ingredient. The pack may for example comprise metal or plastic foil, such as a blister pack. The pack or dispenser device may be accompanied by instructions for administration. 4.4 Assays to Identity Therapeutics Based on the identification of mutations that cause or contribute to the development of osteoporosis, the invention further features cell-based or cell free assays for identifying therapeutics. In one embodiment, a cell expressing an IL-1 receptor, or a receptor for a protein that is encoded by a gene which is in linkage disequilibrium with an IL-1 gene, on the outer surface of its cellular membrane is incubated in the presence of a test compound alone or in the presence of a test compound and another protein and the interaction between the test compound and the receptor or between the protein (preferably a tagged protein) and the receptor is detected, e.g., by using a microphysiometer (McConnell et al. (1992) Science 257:1906). An interaction between the receptor and either the test compound or the protein is detected by the microphysiometer as a change in the acidification ofthe medium. This assay system thus provides a means of identifying molecular antagonists which, for example, function by interfering with protein- receptor interactions, as well as molecular agonist which, for example, function by activating a receptor. Cellular or cell-free assays can also be used to identify compounds which modulate expression of an IL-1 gene or a gene in linkage disequilibrium therewith, modulate translation of an mRNA, or which modulate the stability of an mRNA or protein. Accordingly, in one embodiment, a cell which is capable of producing an IL-1, or other protein is incubated with a test compound and the amount of protein produced in the cell medium is measured and compared to that produced from a cell which has not been contacted with the test compound. The specificity ofthe compound vis a vis the protein can be confirmed by various control analysis, e.g., measuring the expression of one or more control gene. In particular, this assay can be used to determine the efficacy of antisense, ribozyme and triplex compounds. Cell-free assays can also be used to identify compounds which are capable of interacting with a protein, to thereby modify the activity ofthe protein. Such a compound can, e.g., modify the structure of a protein thereby effecting its ability to bind to a receptor. In a preferred embodiment, cell- free assays for identifying such compounds consist essentially in a reaction mixture containing a protein and a test compound or a library of test compounds in the presence or absence of a binding partner. A test compound can be, e.g., a derivative of a binding partner, e.g., a biologically inactive target peptide, or a small molecule. Accordingly, one exemplary screening assay ofthe present invention includes the steps of contacting a protein or functional fragment thereof with a test compound or library of test compounds and detecting the formation of complexes. For detection puφoses, the molecule can be labeled with a specific marker and the test compound or library of test compounds labeled with a different marker. Interaction of a test compound with a protein or fragment thereof can then be detected by determining the level ofthe two labels after an incubation step and a washing step. The presence of two labels after the washing step is indicative of an interaction. An interaction between molecules can also be identified by using real-time BIA (Biomolecular Interaction Analysis, Pharmacia Biosensor AB) which detects surface plasmon resonance (SPR), an optical phenomenon. Detection depends on changes in the mass concentration of macromolecules at the biospecific interface, and does not require any labeling of interactants. In one embodiment, a library of test compounds can be immobilized on a sensor surface, e.g., which forms one wall of a micro-flow cell. A solution containing the protein or functional fragment thereof is then flown continuously over the sensor surface. A change in the resonance angle as shown on a signal recording, indicates that an interaction has occurred. This technique is further described, e.g., in BIAtechnology Handbook by Pharmacia. Another exemplary screening assay ofthe present invention includes the steps of (a) forming a reaction mixture including: (i) an IL- 1 or other protein, (ii) an appropriate receptor, and (iii) a test compound; and (b) detecting interaction ofthe protein and receptor. A statistically significant change (potentiation or inhibition) in the interaction ofthe protein and receptor in the presence ofthe test compound, relative to the interaction in the absence ofthe test compound, indicates a potential antagonist (inhibitor). The compounds of this assay can be contacted simultaneously. Alternatively, a protein can first be contacted with a test compound for an appropriate amount of time, following which the receptor is added to the reaction mixture. The efficacy ofthe compound can be assessed by generating dose response curves from data obtained using various concentrations ofthe test compound. Moreover, a control assay can also be performed to provide a baseline for comparison. Complex formation between a protein and receptor may be detected by a variety of techniques. Modulation ofthe formation of complexes can be quantitated using, for example, detectably labeled proteins such as radiolabeled, fluorescently labeled, or enzymatically labeled proteins or receptors, by immunoassay, or by chromatographic detection. Typically, it will be desirable to immobilize either the protein or the receptor to facilitate separation of complexes from uncomplexed forms of one or both of the proteins, as well as to accommodate automation ofthe assay. Binding of protein and receptor can be accomplished in any vessel suitable for containing the reactants. Examples include microtitre plates, test tubes, and micro-centrifuge tubes. In one embodiment, a fusion protein can be provided which adds a domain that allows the protein to be bound to a matrix. For example, glutathione-S-transferase fusion proteins can be adsorbed onto glutathione sepharose beads (Sigma Chemical, St. Louis, MO) or glutathione derivatized microtitre plates, which are then combined with the receptor, e.g. an 35s-labeled receptor, and the test compound, and the mixture incubated under conditions conducive to complex formation, e.g. at physiological conditions for salt and pH, though slightly more stringent conditions may be desired. Following incubation, the beads are washed to remove any unbound label, and the matrix immobilized and radiolabel determined directly (e.g. beads placed in scintillant), or in the supernatant after the complexes are subsequently dissociated. Alternatively, the complexes can be dissociated from the matrix, separated by SDS-PAGE, and the level of protein or receptor found in the bead fraction quantitated from the gel using standard electrophoretic techniques such as described in the appended examples. Other techniques for immobilizing proteins on matrices are also available for use in the subject assay. For instance, either protein or receptor can be immobilized utilizing conjugation of biotin and streptavidin. Transgenic animals can also be made to identify agonists and antagonists or to confirm the safety and efficacy of a candidate therapeutic. Transgenic animals ofthe invention can include non-human animals containing a restenosis causative mutation under the control of an appropriate endogenous promoter or under the control of a heterologous promoter. The transgenic animals can also be animals containing a transgene, such as reporter gene, under the control of an appropriate promoter or fragment thereof. These animals are useful, e.g., for identifying drugs that modulate production of an IL-1 protein, such as by modulating gene expression. Methods for obtaining transgenic non-human animals are well known in the art. In preferred embodiments, the expression ofthe causative mutation is restricted to specific subsets of cells, tissues or developmental stages utilizing, for example, cis-acting sequences that control expression in the desired pattern. In the present invention, such mosaic expression of a protein can be essential for many forms of lineage analysis and can additionally provide a means to assess the effects of, for example, expression level which might grossly alter development in small patches of tissue within an otherwise normal embryo. Toward this end, tissue-specific regulatory sequences and conditional regulatory sequences can be used to control expression ofthe mutation in certain spatial patterns. Moreover, temporal patterns of expression can be provided by, for example, conditional recombination systems or prokaryotic transcriptional regulatory sequences. Genetic techniques, which allow for the expression of a mutation can be regulated via site-specific genetic manipulation in vivo, are known to those skilled in the art. The transgenic animals ofthe present invention all include within a plurality of their cells a causative mutation transgene ofthe present invention, which transgene alters the phenotype ofthe "host cell". In an illustrative embodiment, either the crelloxP recombinase system of bacteriophage PI (Lakso et al. (1992) PNAS 89:6232-6236; Orban et al. (1992) PNAS 89:6861-6865) or the FLP recombinase system of Saccharomyces cerevisiae (O'Gorman et al. (1991) Science 251:1351-1355; PCT publication WO 92/15694) can be used to generate in vivo site-specific genetic recombination systems. Cre recombinase catalyzes the site-specific recombination of an intervening target sequence located between loxP sequences. loxP sequences are 34 base pair nucleotide repeat sequences to which the Cre recombinase binds and are required for Cre recombinase mediated genetic recombination. The orientation oϊloxP sequences determines whether the intervening target sequence is excised or inverted when Cre recombinase is present (Abremski et al. (1984) J. Biol Chem. 259:1509-1514); catalyzing the excision ofthe target sequence when the loxP sequences are oriented as direct repeats and catalyzes inversion of the target sequence when loxP sequences are oriented as inverted repeats. Accordingly, genetic recombination ofthe target sequence is dependent on expression ofthe Cre recombinase. Expression ofthe recombinase can be regulated by promoter elements which are subject to regulatory control, e.g., tissue-specific, developmental stage-specific, inducible or repressible by externally added agents. This regulated control will result in genetic recombination ofthe target sequence only in cells where recombinase expression is mediated by the promoter element. Thus, the activation of expression ofthe causative mutation transgene can be regulated via control of recombinase expression. Use ofthe crelloxP recombinase system to regulate expression of a causative mutation transgene requires the construction of a transgenic animal containing transgenes encoding both the Cre recombinase and the subject protein. Animals containing both the Cre recombinase and the restenosis causative mutation transgene can be provided through the construction of "double" transgenic animals. A convenient method for providing such animals is to mate two transgenic animals each containing a transgene. Similar conditional transgenes can be provided using prokaryotic promoter sequences which require prokaryotic proteins to be simultaneous expressed in order to facilitate expression ofthe transgene. Exemplary promoters and the corresponding trans- activating prokaryotic proteins are given in U.S. Patent No. 4,833,080. Moreover, expression ofthe conditional transgenes can be induced by gene therapy-like methods wherein a gene encoding the transactivating protein, e.g. a recombinase or a prokaryotic protein, is delivered to the tissue and caused to be expressed, such as in a cell-type specific manner. By this method, the transgene could remain silent into adulthood until "turned on" by the introduction ofthe transactivator. In an exemplary embodiment, the "transgenic non-human animals" ofthe invention are produced by introducing transgenes into the germline ofthe non-human animal. Embryonal target cells at various developmental stages can be used to introduce transgenes. Different methods are used depending on the stage of development ofthe embryonal target cell. The specific line(s) of any animal used to practice this invention are selected for general good health, good embryo yields, good pronuclear visibility in the embryo, and good reproductive fitness. In addition, the haplotype is a significant factor. For example, when transgenic mice are to be produced, strains such as C57BL/6 or FVB lines are often used (Jackson Laboratory, Bar Harbor, ME). Preferred strains are those with H-2^, H-2 d or H-2 Q haplotypes such as C57BL/6 or DBA/1. The line(s) used to practice this invention may themselves be transgenics, and/or may be knockouts (i.e., obtained from animals which have one or more genes partially or completely suppressed) . In one embodiment, the transgene construct is introduced into a single stage embryo. The zygote is the best target for microinjection. In the mouse, the male pronucleus reaches the size of approximately 20 micrometers in diameter which allows reproducible injection of 1-2 pi of DNA solution. The use of zygotes as a target for gene transfer has a major advantage in that in most cases the injected DNA will be incoφorated into the host gene before the first cleavage (Brinster et al. (1985) PNAS 82:4438-4442). As a consequence, all cells ofthe transgenic animal will carry the incoφorated transgene. This will in general also be reflected in the efficient transmission ofthe transgene to offspring of the founder since 50% ofthe germ cells will harbor the transgene. Normally, fertilized embryos are incubated in suitable media until the pronuclei appear. At about this time, the nucleotide sequence comprising the transgene is introduced into the female or male pronucleus as described below. In some species such as mice, the male pronucleus is preferred. It is most preferred that the exogenous genetic material be added to the male DNA complement ofthe zygote prior to its being processed by the ovum nucleus or the zygote female pronucleus. It is thought that the ovum nucleus or female pronucleus release molecules which affect the male DNA complement, perhaps by replacing the protamines ofthe male DNA with histones, thereby facilitating the combination ofthe female and male DNA complements to form the diploid zygote. Thus, it is prefeπed that the exogenous genetic material be added to the male complement of DNA or any other complement of DNA prior to its being affected by the female pronucleus. For example, the exogenous genetic material is added to the early male pronucleus, as soon as possible after the formation ofthe male pronucleus, which is when the male and female pronuclei are well separated and both are located close to the cell membrane. Alternatively, the exogenous genetic material could be added to the nucleus ofthe sperm after it has been induced to undergo decondensation. Sperm containing the exogenous genetic material can then be added to the ovum or the decondensed sperm could be added to the ovum with the transgene constructs being added as soon as possible thereafter. Introduction ofthe transgene nucleotide sequence into the embryo may be accomplished by any means known in the art such as, for example, microinjection, electroporation, or lipofection. Following introduction ofthe transgene nucleotide sequence into the embryo, the embryo may be incubated in vitro for varying amounts of time, or reimplanted into the surrogate host, or both. In vitro incubation to maturity is within the scope of this invention. One common method in to incubate the embryos in vitro for about 1-7 days, depending on the species, and then reimplant them into the surrogate host. For the puφoses of this invention a zygote is essentially the formation of a diploid cell which is capable of developing into a complete organism. Generally, the zygote will be comprised of an egg containing a nucleus formed, either naturally or artificially, by the fusion of two haploid nuclei from a gamete or gametes. Thus, the gamete nuclei must be ones which are naturally compatible, i.e., ones which result in a viable zygote capable of undergoing differentiation and developing into a functioning organism. Generally, a euploid zygote is preferred. If an aneuploid zygote is obtained, then the number of chromosomes should not vary by more than one with respect to the euploid number ofthe organism from which either gamete originated. In addition to similar biological considerations, physical ones also govern the amount (e.g., volume) of exogenous genetic material which can be added to the nucleus ofthe zygote or to the genetic material which forms a part ofthe zygote nucleus. If no genetic material is removed, then the amount of exogenous genetic material which can be added is limited by the amount which will be absorbed without being physically disruptive. Generally, the volume of exogenous genetic material inserted will not exceed about 10 pico liters. The physical effects of addition must not be so great as to physically destroy the viability ofthe zygote. The biological limit ofthe number and variety of DNA sequences will vary depending upon the particular zygote and functions ofthe exogenous genetic material and will be readily apparent to one skilled in the art, because the genetic material, including the exogenous genetic material, ofthe resulting zygote must be biologically capable of initiating and maintaining the differentiation and development ofthe zygote into a functional organism. The number of copies ofthe transgene constructs which are added to the zygote is dependent upon the total amount of exogenous genetic material added and will be the amount which enables the genetic transformation to occur. Theoretically only one copy is required; however, generally, numerous copies are utilized, for example, 1,000-20,000 copies ofthe transgene construct, in order to insure that one copy is functional. As regards the present invention, there will often be an advantage to having more than one functioning copy of each ofthe inserted exogenous DNA sequences to enhance the phenotypic expression ofthe exogenous DNA sequences. Any technique which allows for the addition ofthe exogenous genetic material into nucleic genetic material can be utilized so long as it is not destructive to the cell, nuclear membrane or other existing cellular or genetic structures. The exogenous genetic material is preferentially inserted into the nucleic genetic material by microinjection. Microinjection of cells and cellular structures is known and is used in the art. Reimplantation is accomplished using standard methods. Usually, the surrogate host is anesthetized, and the embryos are inserted into the oviduct. The number of embryos implanted into a particular host will vary by species, but will usually be comparable to the number of off spring the species naturally produces. Transgenic offspring ofthe surrogate host may be screened for the presence and/or expression ofthe transgene by any suitable method. Screening is often accomplished by Southern blot or Northern blot analysis, using a probe that is complementary to at least a portion ofthe transgene. Western blot analysis using an antibody against the protein encoded by the transgene may be employed as an alternative or additional method for screening for the presence ofthe transgene product. Typically, DNA is prepared from tail tissue and analyzed by Southern analysis or PCR for the transgene. Alternatively, the tissues or cells believed to express the transgene at the highest levels are tested for the presence and expression ofthe transgene using Southern analysis or PCR, although any tissues or cell types may be used for this analysis. Alternative or additional methods for evaluating the presence ofthe transgene include, without limitation, suitable biochemical assays such as enzyme and/or immunological assays, histological stains for particular marker or enzyme activities, flow cytometric analysis, and the like. Analysis ofthe blood may also be useful to detect the presence ofthe transgene product in the blood, as well as to evaluate the effect ofthe transgene on the levels of various types of blood cells and other blood constituents. Progeny ofthe transgenic animals may be obtained by mating the transgenic animal with a suitable partner, or by in vitro fertilization of eggs and/or sperm obtained from the transgenic animal. Where mating with a partner is to be performed, the partner may or may not be transgenic and/or a knockout; where it is transgenic, it may contain the same or a different transgene, or both. Alternatively, the partner may be a parental line. Where in vitro fertilization is used, the fertilized embryo may be implanted into a surrogate host or incubated in vitro, or both. Using either method, the progeny may be evaluated for the presence ofthe transgene using methods described above, or other appropriate methods. The transgenic animals produced in accordance with the present invention will include exogenous genetic material. Further, in such embodiments the sequence will be attached to a transcriptional control element, e.g., a promoter, which preferably allows the expression ofthe transgene product in a specific type of cell. Retroviral infection can also be used to introduce the transgene into a non- human animal. The developing non-human embryo can be cultured in vitro to the blastocyst stage. During this time, the blastomeres can be targets for retroviral infection (Jaenich, R. (1976) PNAS 73:1260-1264). Efficient infection ofthe blastomeres is obtained by enzymatic treatment to remove the zona pellucida (Manipulating the Mouse Embryo, Hogan eds. (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1986). The viral vector system used to introduce the transgene is typically a replication-defective retrovirus carrying the transgene (Jahner et al. (1985) PNAS 82:6927-6931; Van der Putten et al. (1985) PNAS 82:6148-6152). Transfection is easily and efficiently obtained by culturing the blastomeres on a monolayer of virus-producing cells (Van der Putten, supra; Stewart et al. (1987) EMBO J. 6:383-388). Alternatively, infection can be performed at a later stage. Virus or virus-producing cells can be injected into the blastocoele (Jahner et al. (1982) Nature 298:623-628). Most ofthe founders will be mosaic for the transgene since incoφoration occurs only in a subset ofthe cells which formed the transgenic non-human animal. Further, the founder may contain various retroviral insertions ofthe transgene at different positions in the genome which generally will segregate in the offspring. In addition, it is also possible to introduce transgenes into the germ line by intrauterine retroviral infection ofthe midgestation embryo (Jahner et al. (1982) supra). A third type of target cell for transgene introduction is the embryonal stem cell (ES). ES cells are obtained from pre-implantation embryos cultured in vitro and fused with embryos (Evans et al. (1981) Nature 292:154-156; Bradley et al. (1984) Nature 309:255-258; Gossler et al. (1986) PNAS 83: 9065-9069; and Robertson et al. (1986) Nature 322:445-448). Transgenes can be efficiently introduced into the ES cells by DNA transfection or by retrovirus-mediated transduction. Such transformed ES cells can thereafter be combined with blastocysts from a non-human animal. The ES cells thereafter colonize the embryo and contribute to the germ line ofthe resulting chimeric animal. For review see Jaenisch, R. (1988) Science 240:1468-1474. The present invention is further illustrated by the following examples which should not be construed as limiting in any way. The contents of all cited references (including literature references, issued patents, published patent applications as cited throughout this application) are hereby expressly incoφorated by reference. The practice of the present invention will employ, unless otherwise indicated, conventional techniques that are within the skill ofthe art. Such techniques are explained fully in the literature. See, for example, Molecular Cloning A Laboratory Manual, (2nd ed., Sambrook, Fritsch and Maniatis, eds., Cold Spring Harbor Laboratory Press: 1989); DNA Cloning, Volumes I and II (D. N. Glover ed., 1985); Oligonucleotide Synthesis (M. J. Gait ed., 1984); U.S. Patent No. 4,683,195; U.S. Patent No. 4,683,202; and Nucleic Acid Hybridization (B. D. Hames & S. J. Higgins eds., 1984). 5. EXAMPLES Example 1 Osteoporosis Association Studies UCSF Association Study A cohort of 1,071 subjects participating in the Study of Osteoporotic Fractures ofthe University of California at San Francisco Association was genotyped for genotypic markers in the IL-1 gene cluster, using techniques, which are known in the art. The results ofthe genotyping are presented in Table 1 A. Table IB presents the results of a Hawaiian osteoporosis study, which is further described below. PAGE MISSING AT THE TIME OF PUBLICATION Table 1. Frequency counts of IL-1 gene cluster genotype markers A. UCSF Study of Osteoporotic Fractures (n = 1,071 Caucasian women) Genotype IL-IA (4845) IL-1B(3954) IL-IB (-511) IL-IRN (2018) 1.1 516 (48.2%) 633 (59.1%) 442 (41.3%) 551 (51.4%) 1.2 450 (42%) 377 (35.2%) 496 (46.3%) 434 (40.5%) 2.2 104 (9.7%) 60 (5.6%) 132 (12.3%) 85 (7.9%) missing 1 1 1 1 B. Hawaii Osteoporosis Study (n = 208 Japanese-American women) Genotype IL-IA (4845) IL-1B(3954) IL-IB (-511) IL-IRN (2018) 1.1 169 (82%) 186 (89.4%) 60 (29%) 190 (91.3%) 1.2 35 (17%) 22 (10.6%) 103 (49.8%) 18 (8.7%) 2.2 2 (1%) - (0%) 44 (21.3%) - (0%) missing 2 — 1 — In the random sample control cohort of 626 subjects, 185 non-spine fractures had occurred. These subjects were used for the analysis of "non-spine fractures". Table 2. Genotype frequencies in cases, controls, and cohort sample in UCSF SOF study Hip Fracture Vertebral Fracture Wrist Fracture Cohon Cases Controls Cases Controls Cases Controls (n=216) (n=575) (n=183) (n=588) (n=216) (n=512) (n=62( IL-1 A 1.1 106 283 88 287 100 254 308 (+4845) (49%) (49%) (48%) (49%) (46%) (50%) (49%) 1.2 96 237 78 240 93 213 257 (44%) (41%) (43%) (41%) (43%) (42%) (41%) 2.2 14 55 17 61 23 45 61 (7%) (10%) (9%) (10%) (11%) (66%) (10%) IL-IB 1.1 133 336 109 340 123 299 365 (+3954) (61%) (58%) (59%) (58%) (57%) (58%) (58%) 1.2 75 199 67 207 82 180 219 (35%) (35%) (37%) (35%) (38%) (35%) (35%) 2.2 8 40 7 41 11 33 42 (4%) (7%) (4%) (7%) (5%) (7%) (7%) IL-IB 1.1 98 230 82 228 92 203 247 (-511) (45%) (40%) (45%) (39%) (43%) (40%) (40%) 1.2 87 275 77 291 98 246 303 (40%) (48%) (42%) (49%) (45%) (48%) (48%) 2.2 31 70 24 67 26 63 76 (15%) (12%) (13%) (12%) (12%) (12%) (12%) IL-IRN 1.1 116 294 95 304 110 264 322 (+2018) (54%) (51%) (52%) (52%) (51%) (52%) (51%) 1.2 83 239 73 246 81 215 262 (38%) (42%) (40%) (42%) (37%) (42%) (42%) 2.2 17 42 15 38 25 33 42 (8%) (7%) (8%) (6%) (12%) (6%) (7%) * Includes 185 non-spine fracture subjects As shown in Table 2, allele 2 of IL-IA (+4845) is associated with an increase in the risk of non-spine fractures. In addition, allele 2 of IL-IB (+3954) is associated with a statistically significant increase in the risk of non-spine fractures. In contrast, allele 2 of IL-IRN (+2018) is associated with a significant decrease in the risk of non-spine fractures. Allele 2 of IL-IA (+4845) is associated with an increase in wrist fractures, although not statistically significant (RR=1.8, 95% CI=1.0-3.5). In the total cohort, allele 2 is associated with an increase in risk of wrist fractures. This effect disappears when HRT users are excluded. Increase in risk of fractures shows a gene-dose effect for allele 2 of IL-IA (+4845) and IL-IB (+3954). In particular, the more copies of allele 2, the larger the effect. Decrease of risk of fractures also shows a gene-dose effect for allele 2 of IL-IRN (+2018). Specifically, the more copies of allele 2, the larger the effect. As shown in Table 3 A, these associations are true for the cohort with exclusion of HRT users. As shown in Table 3B, the associations hold up, though not as strong, when the total cohort, including HRT users, is considered. Hip fractures and vertebral spine fractures, on the other hand, do not appear to be associated with any ofthe IL-1 genetic markers. Table 3A: IL-1 Genotype and Fractures, excluding HRT users Non-spine Fracture, RH (95%CI) unadjusted age/BMI adjusted Multiple* adjusted IL-IB (+4845) 1.1 1.0 (REF) 1.0 (REF) 1.0 (REF) 1.2 1.0 (0.7, 1.4) 1.0 (0.7, 1.4) 2.2 1.4 (0.8, 2.5) 1.6 (0.9, 2.8) IL-lB(+3954) 1,1 1.0 (REF) 1.0 (REF) 1.0 (REF) 1,2 1.1 (0.8, 2.5) 1.3 (0.9, 2.8) 2,2 1.8 (1.0, 3.3) 2.0 (1.1, 3.8)# IL- IRA (+2018) 1,1 1.0 (REF) 1.0 (REF) 1.0 (REF) 1,2 0.9 (0.6, 1.3) 0.8 (0.6, 1.2) 0.4(0.2,1.0) 0.4 (0.2, 0.9)# Wrist Fracture, RH (95% CI) unadjusted age/BMI adjusted multiple* adjusted IL-IB (+4845) 1.1 1.0 REF 1.0 (REF) 1.0 (REF) 1.2 1.2(0.8,1.7) 1.1(0.7,1.7) 1.8(0.9,3.4) 1.8(1.0,3.5) *adjusted for age, modified BMI, yrs since menopause, current smoking & alcohol, ERT use, thiaz diuretic use, self-reported health status and diabetes # p<0.05 versus type 1,1 Table 3B: IL-1 Genotype and Fractures, including HRT user (total cohort) Non-spine Fracture, RH (95% CI) unadjusted age/BMI adjusted multiple* adjusted IL-IA (+4845) 1.1 1.0 (REF) 1.0 (REF) 1.0 (REF) 1.2 1.0(0.7,1.3) 0.9(0.7,1.3) 2.2 1.2(0.8,2.0) 1.3(0.8,2.1) IL-IB (+3954) 1.1 1.0 (REF) 1.0 (REF) 1.0 (REF) 1.2 1.2(0.9,1.6) 1.3(0.9,1.7) 2.2 1.4(0.8,2.3) 1.4(0.8,2.4) IL-1RA(+2018) 1.1 1.0 (REF) 1.0 (REF) 1.0 (REF) 1.2 0.9(0.7,1.2) 0.9 (0.6, 1.2) 2.2 0.5(0.2, 1.0)# 0.5(0.2, 1.0)# Wrist Fracture, RH (95% CI) unadjusted age/BMI adjusted multiple* adjusted IL-IB (+4845) 1,1 1.0 (REF) 1.0 (REF) 1.0 (REF) 1,2 1.1 (0.8, 1.5) 1.1 (0.8, 1.6) 1.1 (0.8, 1.5) 2,2 1.3(0.8,2.2) 1.3(0.8,2.2) 1.3(0.7,2.2) IL-1RA(+2018) 1,1 1.0 (REF) 1.0 (REF) 1.0 (REF) 1,2 0.9(0.6,1.2) 0.9(0.6,1.2) 0.9(0.6,1.2) 2,2 1.8 (1.04, 3.0)# 1.9 (1.1, 3.2)# 1.9 (1.1, 3.3)# ♦ adjusted for age, modified BMI, yrs since menopause, current smoking & alcohol, HRT use, thiaz diuretic use, self-reported health status and diabetes # p< 0.05 versus type 1,1 Bone mineral density (BMD) was measured at the calcaneus, distal radius, total hip, femoral neck and spine. The analysis was adjusted for age, bone mineral index (BMI) menopausal status and life style factors. As shown in Tables 4A and 4B, allele 2 of IL-IB (+3954) is associated with significantly higher BMD at the calcaneus, whether HRT users are included or excluded (p< 0.05 for trend; p< 0.05 for genotype [2.2] vs. genotype [1.1]). Allele 2 of IL-IB (-511) is significantly associated with a lower BMD at the calcaneus in the total cohort, including HRT users (p< 0.05 for trend; p< 0.05 for genotype [2.2] vs. genotype [1.1]). Allele 2 of IL-IB (-511) is associated with a trend towards lower BMD at the calcaneus when HRT users are excluded. No consistent pattern of association between IL-1 genotypes and BMD at other sites was found. Table 4A: IL-1 Genotype and Bone Mineral Density (n = 1,070) Mean calcaneal BMD (g/cm2) unadjusted age/BMI adjusted Multiple* adjusted IL-lB(+3954) 1,1 .39 (.005) .39 (.004) .40 (.004) 1,2 .40 (.006) .40 (.005) .40 (.005) 2,2 .43 (.014)+,# .42 (.012)+,# .42 (.012)+,# IL-IB (-511) 1,1 .41 (.006) .41 (.005) .41 (.005) 1,2 .39 (.005) # .40 (.005) .39 (.005) # 2,2 .39 (.011)+,# .39 (.009)+ .39 (.009)+, # Table 4B: IL-1 Genotype and Bone Mineral Density, excluding HRT users Mean calcaneal BMD (g/cm2) unadjusted age/BMI adjusted multiple* adjusted IL-lB(+3954) 1,1 .39 (.005) .39 (.005) 1,2 .40 (.007) .39 (.007) 2,2 .43 (.016)+ .43 (.016) IL-IB (-511) 1,1 40 (.006) .40 (.006) 1,2 40 (.006) .40 (.006) 2,2 38 (.011) .38 (.011) ♦ adjusted for age, modified BMI, yrs since menopause, current smoking & alcohol, ERT use, thiazide diuretic use, self-reported health status and diabetes + p(trend) < .05 # p< .05 vs type 1,1 Rate of bone loss was measured at total hip, femoral neck and calcaneus. As shown in Tables 5A and 5B, allele 2 of IL-IB (-511) is associated with a higher rate of bone loss at the total hip (p<0.05 for trend), for the total cohort and for the cohort with exclusion of HRT users. Genotype [2.2] of IL-IB (-511) is associated with a trend towards a higher rate of bone loss at the calcaneus. Allele 2 of IL-IB (-511) is associated with a trend towards a higher rate of bone loss at the femoral neck. A gene-dose effect for rate of bone loss at the hip for allele 2 of IL-IB (-511) is present. A similar, though not significant association is observed for rate of bone loss at the femoral neck. These results are similar whether HRT users are included (Table 5A) or excluded (Table 5B) in the analysis. Hawaiian Osteoporosis Study 100 participants in the Hawaii Osteoporosis Study with fractures and 100 participants without fractures were genotyped for genotypic markers in the IL-1 gene cluster. The results are presented in Table IB. The participants in the study are all Japanese-American women in their early to mid 80's. The following clinical data were analyzed: spine and non-spine fractures, including and excluding ovariectomies, bone mineral content (BMC) at the distal and proximal radius, and os calcis, including and excluding subjects who had ovariectomies. The analysis was adjusted for age, BMI and duration of estrogen use. Results Allele 2 of IL-1 A (+4845) is strongly associated with an increase in the number of spine and non-spine fractures (pO.Ol 8), regardless whether subjects with or without ovariectomies were included. Allele 2 of IL-IB (-511) is associated with a decrease in BMC ofthe distal radius (p<0.024). Allele 2 of IL-IRN (+2018) is associated with a decrease in BMC at the os calcis (p<0.022). DISCUSSION OF FINDINGS Role of Ethnicity The distribution of genotypes in the IL-1 gene cluster is very different for Americans with Caucasian ancestry and Japanese- Americans, many of whom in this specific study are first generation immigrants. Distinctly different distribution patterns have been found for other ethnic groups, notably: Chinese (very low frequency of allele 2 of IL-IRN (+2018) and IL-IB (+3954)); African-Americans (pattern similar to the Japanese population); and Hispanics (distribution pattern similar to European Caucasians. This is specifically true for Hispanics from European ancestry. However, the pattern is not very different in Mexican Hispanics with European ancestry). Therefore the genotype of IL- 1 RN (+2018) may not accurately reflect the biological pattern and response. IL-IB (-511) may be a more accurate indicator for that specific haplotype and genotype pattern. Similarly, IL-IB (+3954) may not be an accurate marker for the haplotype pattern. IL-IA (+4954) may be a more accurate indicator for that specific haplotype and genotype pattern. Fracture Risk Allele 2 of IL-IA (+4845) and allele 2 of IL-IB (+3954) are associated with increase in fracture risk. This points to an association with haplotype pattern 1 (see figure 3) Calcaneal BMD is associated with allele 2 of IL-IB (+3954) (Haplotype pattern 1) Haplotype pattern 1 results in increased IL-1 a and IL-lb levels and bioactivity, but normal IL-1 receptor antagonist levels. Rate of Bone Loss Rate of bone loss is associated with allele 2 of IL-IB (-511) (Haplotype pattern 2). Haplotype pattern 2 results in normal levels of IL-1, but reduced levels of IL-1 receptor antagonist. The net result is an increase in IL-1 biological activity and response. Bone Mineral Density BMD (or BMC) is associated with allele 2 of either IL-IB (-511) or IL-IRN (+2018) (Haplotype pattern 2) at the calcaneus, and at the distal radius. Increase in BMD at the calcaneus is associated with haplotype pattern 2. BMD at other sites is not significantly associated with IL-1 markers in this study, which may be caused by the specifics ofthe study population resulting in a lack of power in the statistical analysis. Other issues that may play a role in the University of California, San Francisco study population are: better health, better education, participation in the study and a higher socio-economic status.. The process of bone remodeling is regulated by a number of factors, including: bone metabolism, rate of bone loss, peak bone mass, life style factors, genetics, use of prescription drugs and body mass. Osteoporotic fractures are the endpoint in a complex process of bone remodeling, bone loss, and aging. Bone remodeling and thus the likelihood of developing osteoporosis and osteoprotic fractures are regulated by different biological processes at different stages ofthe life cycle. In the first 5-10 years after onset of menopause most rapid bone loss is experienced due to decrease of estrogen levels and increase of IL-1 levels and activity. In this stage increased formation and activation of osteoclasts (due to increased IL-1 levels) drives the process of bone remodeling. The increase in IL-1 levels in the first 5-10 years after menopause may be more important than levels of IL-1 receptor antagonist. Approximately 10 years after menopause, the rate of bone loss slows down, due to a change in the biology of bone remodeling. In this stage the reduced formation of osteob lasts forms the driving force behind bone remodeling. Reduced levels of IL-1 receptor antagonist may form a more important factor in later postmenopausal years in regulating the amount of bone loss. Haplotype pattern 1 is associated with increase in IL-1 a and IL-lb levels and bioactivity, but normal IL-1 receptor antagonist levels. Women with haplotype pattern 1 are likely to experience a larger bone loss during their early menopausal years than women with haplotype pattern 2. Women with haplotype pattem 1 are thus more likely to experience fractures at any stage of life, when no preventive measures or treatment are initiated. Women with haplotype pattern 2 will likely experience more bone loss later in life and may be more susceptible to experience fractures later in life, specifically fractures associated with age-related osteoporosis. Therefore, subjects with haplotype pattern 2, who produce constitutively less IL-lra than subjects with haplotype pattern 1, will experience larger bone loss and reduced bone formation in the later postmenopausal phase of their life. Based on the hypothesis set forth above, it follows that the data reported by Keen et al. (1998) ("Allelic variation in the interleukin-1 receptor antagonist gene is associated with early postmenopausal bone loss at the spine" (Bone 23 (4), 367-371): an association between allele [1] ofthe VNTR in IL-IRN and early postmenopausal bone loss) suggest that the subjects who have allele [1] ofthe VNTR actually carry haplotype pattern 1. Since all ofthe subjects in this study are within 5 years of onset of menopause, their bone loss is regulated by increased levels and activity of IL-1 and not by increased or decreased levels of IL-lra. Since only the VNTR of IL-IRN was determined, the erroneous conclusion was reached that VNTR allele 1 of IL-IRN is important in the changes in bone density and is the main predictor for bone loss and risk of osteoporotic fracture incidence.

Claims: WHAT IS CLAIMED IS: 1. A method for determining whether a female subject is predisposed to developing osteoporosis, comprising identifying the IL-1 haplotype pattern ofthe female, wherein the presence of haplotype pattern 1 indicates that the female is susceptible to larger bone loss and/or increased risk of fracture during the early menopausal years and the presence of haplotype pattern 2 indicates that the female is susceptible to larger bone loss and/or increased risk of fracture during post-menopause. 2. A method of claim 1, wherein said identifying step is selected from the group consisting of: a) allele specific oligonucleotide hybridization; b) size analysis; c) sequencing; d) hybridization; e) 5' nuclease digestion; f) single-stranded conformation polymoφhism; g) allele specific hybridization; h) primer specific extension; and j) oligonucleotide ligation assay. 3. A method of claim 1, wherein prior to or in conjunction with the identifying step, the nucleic acid sample is subject to an amplification step. 4. A method of claim 2, wherein said size analysis is preceded by a restriction enzyme digestion. 5. A method for selecting an appropriate osteoporosis therapy for a female subject, comprising the steps of: (a) identifying the IL-1 haplotype pattern ofthe female, wherein the presence of haplotype pattern 1 indicates that the female is susceptible to larger bone loss and/or increased risk of fracture during the early menopausal years and the presence of haplotype pattern 2 indicates that the female is susceptible to larger bone loss and/or increased risk of fracture during post-menopause ; and (b) and selecting a therapeutic that compensates for or otherwise modulates the net bioactivity resulting from the haplotype pattern. 6. A method of claim 5, wherein said identifying step is performed using a technique selected from the group consisting of: a) allele specific oligonucleotide hybridization; b) size analysis; c) sequencing; d) hybridization; e) 5' nuclease digestion; f) single-stranded conformation polymoφhism; g) allele specific hybridization; h) primer specific extension; and j) oligonucleotide ligation assay. 7. A method of claim 5, wherein prior to or in conjunction with the identifying step, the nucleic acid sample is subjected to an amplification step. 8. A method of claim 6, wherein said size analysis is preceded by a restriction enzyme digestion. 9. A method of claim 5, wherein the therapeutic is a modulator of an IL-1 activity. 10. A method of claim 9, wherein the IL-1 activity is IL-lα. 11. A method of claim 9, wherein the IL- 1 activity is IL- 1 β . 12. A method of claim 9, wherein the IL-1 activity is IL-IRN. 13. A method of claim 9, wherein the modulator of an IL-1 activity is a protein, peptide, peptidomimetic, small molecule, nucleic acid or a nutraceutical. 14. A method of claim 9, wherein the modulator is an agonist. 15. A method of claim 9, wherein the modulator is an antagonist. 16. A method for determining the effectiveness of treating a subject that has or is predisposed to developing osteoporosis with a particular dose of a particular therapeutic, comprising the steps of: a) detecting the level, amount or activity of an IL-1 protein; or an IL-1 mRNA or DNA in a sample obtained from a subject; b) administering the particular dose ofthe particular therapeutic to the subject; detecting the level, amount or activity of an IL-1 protein; or an IL-1 mRNA or DNA in a sample obtained from a subject; and c) comparing the relative level, amount or activity obtained in step a) with the level, amount or activity obtained in step b). 17. A method of claim 16, wherein the therapeutic is a modulator of an IL-1 activity. 18. A method of claim 17, wherein the IL-1 activity is IL-lα. 19. A method of claim 17, wherein the IL-1 activity is IL-lβ. 20. A method of claim 17, wherein the IL-1 activity is IL-IRN 21. A method of claim 16, wherein the therapeutic is a protein, peptide, peptidomimetic, small molecule or a nucleic acid. 22. A method of claim 17, wherein the modulator is an agonist. 23. A method of claim 17, wherein the modulator is an antagonist. 30. A method of claim 28, wherein the IL-1 activity is IL-lβ. 31. A method of claim 28, wherein the IL-1 activity is IL-lRa. 32. A method of claim 24, wherein the therapeutic is a protein, peptide, peptidomimetic, small molecule or a nucleic acid. 33. A method of claim 28, wherein the modulator is an agonist. 34. A method of claim 28, wherein the modulator is an antagonist. 63

Inventors: DUFF GORDON W, VAN DIJK SIMON, DUFF, GORDON, W., VAN DIJK, SIMON
Applicants: DIJK SIMON VAN, DUFF GORDON W, INTERLEUKIN GENETICS INC, DUFF, GORDON, W., INTERLEUKIN GENETICS, INC., VAN DIJK, SIMON
Application year: 2000
Main classification: C12Q1
IPC codes: A61K31, A61K38, A61K39, A61K45, A61K48, A61P19, C07H21, C12N15, C12P19, C12Q1, G01N33